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Summary 
The Exploration Medical Capability project is creating a 
catalog of risk assessments using the Integrated Medical 
Model (IMM). The IMM is a software-based system intended 
to assist mission planners in preparing for spaceflight missions 
by helping them to make informed decisions about medical 
preparations and supplies for combating and treating various 
medical events. IMM uses Probabilistic Risk Assessment, 
which deals with low-probability, high-consequence events of 
complex physiological processes, although high-probability, 
low-consequence events are also of interest. The objective is 
to use statistical analyses to inform the IMM decision tool 
with estimated probabilities of medical events occurring dur-
ing an exploration mission. Because data regarding astronaut 
health are limited, Bayesian statistical analysis is used. 
Bayesian inference combines prior knowledge, such as data 
from the general U.S. population, the U.S. Submarine Force, 
or the analog astronaut population located at the NASA 
Johnson Space Center, with observed data for the medical 
condition of interest. The posterior results reflect the best 
evidence for specific medical events occurring in flight. 
Bayes’ theorem provides a formal mechanism for combining 
available observed data with data from similar studies to 
support the quantification process. This is especially relevant 
when dealing with physiological data from the astronaut corps, 
where data are relatively sparse (zero in some cases). Bayes’ 
theorem depends on the consideration of all uncertainties 
(both known and unknown) that are fundamental to the 
assessment of risk. All Bayesian updates were performed 
using the open-source numerical update code called the 
Bayesian inference Using Gibbs Sampling (WinBUGS). 
WinBUGS is a computer software program that uses Markov-
chain Monte Carlo methods to perform Bayesian analysis of 
complex statistical models. 
The IMM team performed Bayesian updates on the follow-
ing medical events: angina, appendicitis, atrial fibrillation, 
atrial flutter, dental abscess, dental caries, dental periodontal 
disease, gallstone disease, herpes zoster, renal stones, seizure, 
and stroke.  
1.0 Introduction 
The Integrated Medical Model (IMM) is a software-based 
system that will quantify health risks, identify medical needs, 
develop potential mitigation procedures, and assist in the 
preparation of spaceflight missions. Because data regarding 
astronaut health are limited, the IMM team used Bayesian 
statistical analysis. Bayesian inference combines prior knowl-
edge, such as data from a similar study, with observed data for 
the event of interest. The outcome is a posterior result that 
reflects the best evidence for specific medical events occurring 
in flight. The IMM team performed Bayesian updates on the 
following medical events: angina, appendicitis, atrial fibrilla-
tion, atrial flutter, dental abscess, dental caries, dental perio-
dontal disease, gallstone disease, herpes zoster, renal stones, 
seizure, and stroke.  
1.1 Bayesian Analysis 
Because classical statistical techniques are not suitable for 
assessing the risk of low-probability, high-consequence 
events, an alternative risk-modeling framework, Probabilistic 
Risk Assessment (PRA), was developed that works within a 
scenario-based concept of risk that best informs decision 
making (Ref. 1). PRA integrates a collection of models and 
quantifies integral risk metrics and their uncertainties (e.g., the 
probability of the loss of crew and the associated uncertainty). 
This modeling framework is supported by the application of 
Bayes’ theorem of probability. The theorem provides a formal 
mechanism for combining all available information, such as 
engineering and qualification test data, field experience, expert 
judgment, and data from similar systems to support the 
quantification process. This is especially relevant when 
dealing with astronaut medical event data, which are relatively 
sparse (zero in some cases). Bayes’ theorem depends on an 
honest treatment of the uncertainties that are fundamental to 
risk assessment and is based on a subjective interpretation of 
probability (Ref. 1). 
Within PRA aleatory models, most of the parameters are 
uncertain. This layer of imprecision is defined as epistemic 
uncertainty, which represents how accurate the developer’s 
state of knowledge is about the model, regardless of the model 
type. If an aleatory model is used (e.g., binomial) or a deter-
ministic model is used (e.g., a fault tree), and if any parameter 
of these models is uncertain, then the model has epistemic 
uncertainty. Bayesian quantification methods are utilized to 
determine the nature of the epistemic uncertainty. In the 
Bayesian approach, probability quantifies the degree of belief 
and is used to describe the plausibility of an event. Frequentist 
inference generally relies on a mathematically consistent way 
to incorporate nonempirical data, which allows for the 
propagation of uncertainties throughout the logic model 
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(Ref. 1). Often this approach is not available for astronaut 
medical event data. A solution is to incorporate Bayesian 
analysis, allowing for an alternative interpretation of probabil-
ity. Information about the parameter, beyond what is in the 
data, is included in the estimate, and Monte Carlo sampling is 
used to propagate uncertainties through the logic analysis.  
Some of the typical uncertainties associated with PRA 
assumptions include disagreement or lack of accuracy when 
the probabilities of physical processes are estimated, limited 
knowledge of the parameters in phenomenological equations, 
unknown parameter values, inaccurate parameter values, and 
the inherent variability of stochastic processes. The Bayesian 
approach provides a formal mechanism for combining all 
available information, such as engineering and qualification 
test data, field experience, expert judgment, and data from 
similar systems. The types of information available for 
parameter values might include prior data—general engineer-
ing knowledge and historical information from similar 
events—and observed data for the event of interest in the 
system under study. 
1.2 Methods 
For the medical events investigated in this study, the 
astronaut population and the occurrences are very low. 
Consequently, Bayesian methods were deemed to be nec-
essary to produce better estimates of the probable incidence 
rates. The Bayesian process allows researchers to make 
inferences to determine the probability that a hypothesis is 
true, conditional on all available evidence. In these Bayesian 
updates, preflight and in-flight astronaut data (obtained from 
the Lifetime Surveillance of Astronaut Health (LSAH), see 
Appendix A) became the experimental data, and prior data 
were found through a variety of sources, including the general 
U.S. population, the U.S. Submarine Force, and the analog 
astronaut population at the NASA Johnson Space Center. The 
analog population is a group of people with similar physio-
logical characteristics such as age, height, weight, health 
conditions, and lifestyles—including activity levels and health 
habits—as members of the astronaut corps. Preflight and 
in-flight calculations varied slightly for different medical 
events, based on when specific medical events started being 
tracked by LSAH and what data were available at the time of 
the specific request (Ref. 2). The renal stone data request was 
the first request made to LSAH, and in-flight astronaut data 
for this medical event includes shuttle transport system mis-
sions (STS–1 to STS–114), International Space Station 
missions (Expeditions 1 to 8 and 10 to 13), and Mir missions 
(seven astronauts total). The subsequent requests (in chrono-
logical order of request) were stroke, appendicitis, dental 
problems (abscess, caries, and periodontal disease), herpes 
zoster, atrial fibrillation, and atrial flutter (requests made  
in June 2010), and angina, seizure, and gallstone disease 
(requests made in December 2010).  
All prior data used to define the incidence rate were  
assumed to be lognormal. The Poisson distribution was chosen 
to be the governing probability distribution (i.e., likelihood) 
for incidence values because it includes time (person-years) as 
an element in the probability equation. Time is an essential 
variable because it allows the probabilities to increase as the 
time of a space mission increases. Because Poisson distri-
butions were used, an average rate for the incidences of these 
medical events had to be assumed. Consequently, the 
Bayesian update approach was used to calculate the distri-
bution (mean and uncertainty) of the incidence rate associated 
with the Poisson distribution, and this approach is described 
for each of the medical events addressed in the report.  
When Bayesian analyses are performed, certain data must 
be present for the calculations. For the prior data, the mean 
incidence rate and the error factor (EF) were required to 
adequately parameterize the assumed lognormal distribution. 
The EF represents the variance in the model, which is defined 
as the square root of the ratio of the 95th and 5th percentiles. 
This definition for the EF can be leveraged to relate percen-
tiles of the standard normal distribution to define the percen-
tiles of the lognormal distribution as illustrated by Bedford 
and Cooke (Ref. 3). In this case, 
 ln(EF) = Φ(0.95) × σ = 1.645 × σ  
where σ is the standard deviation, Φ is the cumulative distri-
bution function, 0.95 is the standard deviation at the 95th 
percentile of the distribution, and 1.645 is a constant repre-
senting the value of Φ at 0.95. For additional discussion on 
how the EF can be calculated from the confidence interval 
(CI) (see Appendix B).  
The numerical update code called Bayesian inference 
Using Gibbs Sampling (WinBUGS) was used to perform all 
Bayesian updates. WinBUGS is a computer software pro-
gram that performs Bayesian analysis of complex statistical 
models using Markov-chain Monte Carlo methods. It grew 
from a statistical research project at the Medical Research 
Council Biostatistics Unit, but it is now being developed 
jointly with the Imperial College School of Medicine at 
St. Mary’s, London. This open-source software is available 
on the Web. 
In most cases, the Bayesian process followed a standardized 
approach that combined the prior data with observed astronaut 
incidence data. Depending on the medical event, two or more 
Bayesian updates had to be performed with WinBUGS to 
adequately capture all the available data relating to the 
condition being examined. Appendix C provides the proce-
dures that were used to construct and implement multiple 
Bayesian analyses of each medical event. An outline of the 
general procedure for completing a Bayesian update follows 
(Ref. 1): 
 
(1) Begin with a probabilistic model for the process of 
interest and encode the aleatory uncertainty. For these 
analyses, this involves identifying the conditions that 
most affect the event, the type of data (incidence rates), 
and how the conditions and data are represented. 
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(2) Specify a prior distribution for the parameter(s) in this 
update, quantifying epistemic uncertainty (quantifying 
the degree of belief about the possible parameter 
values). For the IMM Bayesian analysis, this involved  
reviewing data identified in the Clinical Findings Form 
and reviewing the literature to capture appropriate 
(multistep) prior data.  
(3) Obtain the observed data for the population of interest. 
Here data from the LSAH were heavily leveraged to 
support the reserved data requirements. In the case of 
no known incidents, only the total observation times in 
the appropriate segregated time span (in-flight and pre-
flight) were required. 
(4) Obtain the posterior (i.e., updated) distribution for the 
parameter(s) of interest. Here one or more WinBUGS 
scripts were created to perform the Markov-chain inte-
gration of the Bayesian analysis.  
(5) Check the validity of the output. Output validity has 
several meanings, including convergence of the Markov 
chain, indicating that an appropriate representation of 
the data has been numerically determined, as well as the 
adequacy of the integrated calculations to represent the 
true understanding of the incidence rate and the  
associated uncertainty. 
 
For this analysis, 75 000 Monte Carlo samplings were used 
for all medical events because this was a relatively safe 
indication that the Markov chain had reached its steady state. 
As rule of thumb for convergence, the WinBUGS manual 
suggests running until the Monte Carlo error is <5 percent of 
the sample mean or until the Brooks-Gelman-Rubin statistic is 
<1.2. These conditions were achieved with 75 000 samples in 
all cases. Analysis validity was confirmed through review with 
IMM team subject matter experts with regard to both the 
process and the analysis findings.  
2.0 Medical Events 
The following medical events were analyzed: angina, 
appendicitis, atrial fibrillation, atrial flutter, dental abscess, 
dental caries, dental periodontal disease, gallstone disease, 
herpes zoster, renal stones, seizure, and stroke. 
2.1 Angina Pectoris 
Angina pectoris is chest pain that occurs when part of the 
heart muscle does not get enough oxygenated blood. It is not  
a disease, but is typically a symptom of coronary heart 
disease—the most common type of heart disease in adults  
and occurs when plaque builds up on the inner walls of the 
coronary arteries, which can lead to a heart attack (Ref. 4). 
There are several different types of angina: stable, unstable, 
variant (Prinzmetal’s angina), and microvascular. The most 
common type of angina is stable angina, which has a regular 
pattern and occurs when the heart is working harder than usual 
(Ref. 4). Stable angina is not a heart attack, but it can suggest 
that a heart attack is more likely in the future. There are many 
different risk factors for angina pectoris, including high 
cholesterol, high blood pressure, smoking, diabetes or insulin 
resistance, being overweight or obese, inactivity, unhealthy 
diet, metabolic syndrome, familial history, and age—angina 
risk increases for males over the age of 45 and females over 
the age of 55 (Ref. 4).  
Because of the potential severe medical problems associated 
with angina pectoris, understanding the probability of angina 
pectoris occurring in flight was deemed to be necessary. 
Incidence rates from the general population (Ref. 5), the 
analog astronaut population, and the active astronaut corps 
(Ref. 6, personal communication) were used to find this 
probability. A Bayesian update was used to combine these 
data to yield a probability distribution for the average inci-
dence of angina pectoris during exploration missions.  
2.1.1 Data and Methods 
The data describing the average rate of angina incidence in 
the general population came from an article in the British 
Heart Journal (Ref. 5). The article follows 110 patients 
(70 males and 40 females) who were 70 years of age or less 
with no history of coronary heart disease when they presented 
for the first time with typical angina. All data were supplied as 
incidences per 1000 person-years and were reported for males 
and females between the ages of 41 and 50. Table 1 reports the 
average rates of angina for males and females, the correspond-
ing 95-percent CIs, and the EFs (which were calculated as 
described in Appendix B, Section B.1). Total CI data (for 
males and females) between the ages of 41 and 50 were not 
presented in this article and were, therefore, not calculated in 
this analysis. 
Incidences of angina in the analog astronaut population per 
person-years were obtained from LSAH (see Table 2 and 
Ref. 6, personal communication) because of the high number 
of risk factors for angina pectoris.  
Incidences of angina in the astronaut corps and the number 
of person-years for preflight and in-flight astronauts were 
obtained from LSAH (see Table 3 and Ref. 6, personal 
communication). There were no cases of angina during any 
point in the study. 
 
TABLE 1.—INCIDENCE OF ANGINA PECTORIS IN ADULTS 
IN THE UNITED KINGDOM 
Statistic Males Females 
Angina incidence in adults 41 to 
50 years of age per 1000 person-years 0.63 0.47 
95-percent confidence interval (CI) for 
angina incidence in adults per 1000 
person-years 0.24 to 1.02 0.12 to 0.82 
Angina incidence in adults 41 to 
50 years of age per person-year 
Error factor (EF) for angina incidence 
in adults 41 to 50 years of age 
6.3×10-4 
 
1.77 
4.7×10-4 
 
2.08 
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TABLE 2.—INCIDENCE OF ANGINA PECTORIS IN  
THE ANALOG ASTRONAUT POPULATION 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females 
Total person-years 2213.0 2808.6 
Angina cases 6 0 
Angina incidence rate, events per person-year 2.71×10–4 0 
 
TABLE 3.—INCIDENCE OF ANGINA PECTORIS IN 
PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females 
Preflight astronauts 
Total person-years 1970.4 264.8 
Angina cases 0 0 
Angina incidence rate, events per person-year 0 0 
In-flight astronauts 
Total person-years 32.0 6.5 
Angina cases 0 0 
Angina incidence rate, events per person-year 0 0 
2.1.2 Bayesian Updates To Improve Estimates of 
Angina Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the angina incidence rate in the astronaut corps 
and to find an approximation suitable for the IMM effort. 
Three steps and Bayesian updates were performed. The first 
step used the general population data (Ref. 5) as priors to 
update the analog astronaut population data (Ref. 6, personal 
communication). This step was performed two times, once 
each for males and females. The posterior results from this 
step describe the angina incidence rates for the analog astro-
naut population. In the second step, the data from these 
posterior results, namely the mean and the 5th and 95th 
percentiles, were used as the priors to update the preflight 
astronaut data for males and females. In the third step, the data 
from the preflight posterior results were used as the priors to 
update the in-flight astronaut data for males and females. 
Ultimately, four probability distributions were found to 
describe the incidence rate for angina in preflight and in-flight 
male and female astronauts. Appendix C provides the code 
used in WinBUGS, and an outline of the input data for each 
step follows. 
Step 1: The general United Kingdom population incidence 
rates per person-year for females and males, and the asso-
ciated EFs from Table 1, were used for the priors in 
WinBUGS. The updated analog astronaut population data 
from LSAH included the number of person-years and the 
number of angina cases for males and females (Table 2). The 
posterior results from this Bayesian update were Poisson 
probability distributions for males and females in the analog 
astronaut population. Table 4 shows the means, 5th and 95th 
percentiles, and standard deviations. 
 
TABLE 4.—RESULTS OF BAYESIAN ANALYSIS  
FOR ANGINA PECTORIS IN THE ANALOG  
ASTRONAUT POPULATION 
Angina incidence rate, λanalog, events per person-year 
Statistic Males Females 
Mean 4.15×10–4 3.72×10–4 
Standard deviation 9.99×10–5 1.55×10–4 
5 percent 2.69×10–4 1.77×10–4 
95 percent 5.93×10–4 6.63×10–4 
 
TABLE 5.—RESULTS OF BAYESIAN ANALYSIS FOR 
ANGINA PECTORIS IN PREFLIGHT MISSION-READY, 
ACTIVE MALE AND FEMALE ASTRONAUTS 
Angina incidence rate, λastronaut, events per person-year 
Statistic Males Females 
Mean 3.96×10–4 3.65×10–4 
Standard deviation 9.38×10–5 1.53×10–4 
5 percent 2.62×10–4 1.74×10–4 
95 percent 5.56×10–4 6.53×10–4 
 
TABLE 6.—RESULTS OF BAYESIAN ANALYSIS  
FOR ANGINA PECTORIS IN IN-FLIGHT  
MALE AND FEMALE ASTRONAUTS 
Angina incidence rate, λastronaut, events per person-year 
Statistic Males Females 
Mean 3.95×10–4 3.64×10–4 
Standard deviation 9.21×10–5 1.53×10–4 
5 percent 2.64×10–4 1.74×10–4 
95 percent 5.61×10–4 6.53×10–4 
 
Step 2: The posterior results from Step 1—the means and 
the 5th and 95th percentiles from Table 4—along with the 
LSAH preflight data in Table 3 were used in WinBUGS to 
update the preflight astronaut data. The posterior results from 
this Bayesian update were Poisson probability distributions for 
angina incidence in preflight male and female astronauts. 
Table 5 shows the means, 5th and 95th percentiles, and 
standard deviations. 
Step 3: The posterior results from Step 2—the means and 
the 5th and 95th percentiles from Table 5, along with the 
LSAH in-flight data in Table 3 were used in WinBUGS to 
update the in-flight astronaut data. The posterior results from 
this Bayesian update were Poisson probability distributions for 
angina incidence in in-flight male and female astronauts. 
Table 6 shows the means, 5th and 95th percentiles, and 
standard deviations. 
2.1.3 Discussion 
This analysis should be considered rather limited because it 
assumes an average incidence rate of angina pectoris, with no 
specific data for important factors such as overall health, diet, 
activity levels, metabolic syndrome, and familial history. The 
general population data from Gandhi et al. (Ref. 5) include a 
large proportion of smokers and ex-smokers (34 and 
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43 percent, respectively) and a large proportion of individuals 
classified as overweight and obese (50 and 27 percent, 
respectively). An individual was classified as overweight if he 
or she had a body mass index of 25 to 29 kg/m2, and an 
individual was classified as obese if he or she had a body mass 
index greater than or equal to 30 kg/m2. In addition, there may 
be minor differences between the diets and lifestyles of the 
United Kingdom population used in Gandhi et al. and the U.S. 
astronaut population. However, both populations are from 
well-developed, industrial countries in similar temperate 
regions. Accordingly, the present analysis assumes that their 
diets are similar to a high degree. The use of the analog 
astronaut population data may help to counteract some of the 
inaccuracies from these differences. The analog astronaut 
population may more closely reflect the actual risk factors that 
might influence an astronaut’s propensity to develop angina 
pectoris. In spite of the limitations, the assumptions, and the 
data available, this analysis is probably a reasonable approxi-
mation of the incidence of angina pectoris during exploration 
missions. The current results can serve as a baseline for future 
studies that include more data and risk parameters.  
2.2 Appendicitis 
Because appendicitis may greatly affect the performance, 
health, and morale of crewmembers, evaluating the probability 
that an astronaut may encounter appendicitis during an 
exploration mission was deemed to be necessary. Appendici-
tis, the inflammation of the appendix, could be life-threatening 
for a crewmember lacking immediate medical care. The 
probability of an astronaut encountering appendicitis was 
estimated using data from the general U.S. population (Refs. 7 
and 8) as well as from astronaut data from LSAH (Ref. 9, 
personal communication). A Bayesian update was used to 
combine the incidence rates from these sources to estimate the 
probability distribution for the rate of appendicitis during 
exploration missions.  
2.2.1 Data and Methods 
General population data regarding the incidence rate of 
appendicitis was extracted using a longitudinal, nationally 
representative, population-based study that was conducted on 
the incidence of appendicitis in the general U.S. population by 
the National Ambulatory Medical Care Survey and National 
Hospital Ambulatory Medical Care Survey (3-year average, 
2003 to 2005) (Ref. 8). Because this source does not differen-
tiate gender and ethnicity data by age, incidence rates differ-
entiating between males and females and between whites and 
blacks were not been included in this calculation. Only the 
data for the hospital discharges (all-listed diagnoses) were 
included, because these data are presumably more reliable 
than data from ambulatory care visits. The incidence is 
98/100 000 in females and 118/100 000 in males, for a ratio  
 
TABLE 7.—INCIDENCE OF APPENDICITIS IN U.S. 
ADULTS 45 TO 64 YEARS OF AGE 
Appendicitis incidence in adults 45 to 64 years 
of age per 100 000 persons per yeara  ................................... 93 
Appendicitis incidence rate in adults 45 to 
64 years of age, events per person-year .................... 9.30×10–4 
aAll-listed diagnoses for hospital discharges. 
 
 
 
TABLE 8.—INCIDENCE OF APPENDICITIS IN PREFLIGHT 
AND IN-FLIGHT MISSION-READY, ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 1400 244 1644 
Appendicitis cases 2 0 2 
Appendicitis incidence rate,  
events per person-year 1.43×10–3 0 1.22×10–3 
In-flight astronauts 
Total person-years 31.9 6.4 38.3 
Appendicitis cases 0 0 0 
Appendicitis incidence rate,  
events per person-year 0 0 0 
 
of 1:1.20. Table 7 shows the incidence rate of appendicitis in 
U.S. adults 45 to 64 years of age (Ref. 8). The rate for adults 
45 to 64 years of age was used because it more accurately 
reflects the age of active astronauts and because the inci-
dence rate is lower than that for people 15 to 24 years of age 
(which have the highest incidence rate, Ref. 8). Data from 
Addiss et al. (Ref. 7), which included data for males and 
females that was differentiated by age groups, was used to 
estimate the EF as 1.2.  
Incidences of appendicitis in the analog astronaut popula-
tion were obtained from the LSAH (Ref. 9, personal commu-
nication) and are summarized in Table 8. There were no 
occurrences of appendicitis in in-flight astronauts, and there 
were no occurrences in female astronauts. The highest 
incidence rate was in preflight male astronauts. Because there 
were no age-differentiated data for males and females availa-
ble for the general population, the data for male and female 
astronauts were combined. 
 
2.2.2 Bayesian Updates To Improve Estimates of 
Appendicitis Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of appendicitis in the 
astronaut corps and provide a first-order approximation 
suitable for the IMM effort. General population data (Ref. 8) 
were used to determine an informed lognormal conjugate for 
the incidence rate of appendicitis in the general U.S. popula-
tion (λgeneral). This was used as a prior to update LSAH 
preflight data in Step 1 of the Bayesian implementation,  
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yielding an updated appendicitis incidence rate. In Step 2, the 
posterior result of Step 1 was used as the prior and was 
updated with LSAH in-flight data in WinBUGS. The result 
was an estimation of the appendicitis incidence rate in astro-
nauts during an exploration mission. Appendix C provides the 
code used in WinBUGS as well as the sampling procedure.  
Step 1: First, WinBUGS was informed with the mean inci-
dence rate of the general population from Table 7 and the EF 
(1.2). 
Step 2: The input parameters of Step 1 were used to perform 
a Bayesian update with 75 000 Monte Carlo samples on the 
number of events and time (person-years) from the LSAH 
preflight data (Table 8).  
Step 3: The posterior result of Step 2—the mean incidence 
rate—was dissected and used as the prior for the second 
update. The 5th and 95th percentiles from the lognormal 
Poisson distribution in Step 2 were used to calculate the EF. 
Table 9 shows the results for preflight astronauts. 
Step 4: The input parameters of Step 1 were used to perform 
a second Bayesian update with 75 000 Monte Carlo samples 
on the number of in-flight events and person-years from the 
LSAH in-flight data (Table 8). Appendix C provides details. 
This process returned an estimate of the rate of appendicitis 
in in-flight astronauts with respect to the general population 
(Table 10). This rate can be used as the input rate to a Poisson 
distribution to estimate the probability of appendicitis occur-
ring in flight.  
 
 
 
TABLE 9.—RESULTS OF BAYESIAN ANALYSIS FOR 
APPENDICITIS IN TOTAL PREFLIGHT MISSION-
READY, ACTIVE ASTRONAUTS 
Appendicitis incidence rate, λastronaut, events per person-year 
Mean 9.35×10–4 
Standard deviation 1.04×10–4 
5 percent 7.75×10–4 
Median 9.29×10–4 
95 percent 1.11×10–3 
 
 
 
 
TABLE 10.—RESULTS OF BAYESIAN ANALYSIS 
FOR APPENDICITIS IN TOTAL IN-FLIGHT 
ASTRONAUTS  
Appendicitis incidence rate, λastronaut, events per person-year 
Mean 9.34×10–4 
Standard deviation 1.03×10–4 
5 percent 7.76×10–4 
Median 9.28×10–4 
95 percent 1.11×10–3 
2.2.3 Discussion 
This approximation is limited in that it assumes an average 
incidence rate of appendicitis irrespective of environmental 
conditions and the cause of appendicitis. There also were 
limitations in the data for the general population in that the 
incidence rate data for males and females and for blacks and 
whites were not age-differentiated. Everhart reports that the 
rate in whites was twice that of blacks and that the rate for 
males was 20 percent greater than for females (Ref. 8, these 
statements, however, do not take into account the ages being 
reported). According to another source for general population 
data, the highest incidence rates of appendicitis are found in 
15 to 24 year olds, with 74 percent of all appendicitis cases 
found in 5 to 34 year olds (Ref. 10). In the mission-ready 
astronaut corps, the mean age for females is 43.8 years and the 
mean age for males is 45.3 years. Another assumption was 
made to use only hospital discharge data, not ambulatory care 
data, because patients being discharged from the hospital 
presumably carry a more definitive diagnosis of appendicitis 
because of the availability of better imaging technology and 
the increased likelihood that exploratory surgery was 
conducted (Ref. 8). However, these Bayesian updates yield a 
reasonable representation of the appendicitis incidence rate 
given the occurrence data available and the assumptions made 
during construction of the estimate.  
Future estimates may be more accurate if data for males, 
females, and different ethnicities are available for various age 
ranges. More accurate estimates also could be made with 
further analysis of appendicitis occurrence in post-flight 
astronauts as well as greater understanding of the physiologi-
cal pathways that lead to the obstruction, inflammation, and 
infection of the appendix. The current data will serve as the 
baseline for future estimates that utilize additional physiologi-
cal parameters.  
2.3 Atrial Fibrillation 
One of the most common forms of heart arrhythmias is 
atrial fibrillation (AF). It is characterized by rapid, haphazard 
atrial contractions. Although AF is known to increase the 
likelihood of stroke and can be an underlying factor for death, 
it generally is not immediately threatening. AF is accompanied 
by debilitating symptoms, such as dizziness, shortness of 
breath, heart palpitations, and fatigue. Although these symp-
toms may not pose great difficulties for the general popula-
tion, an AF episode could be detrimental to an astronaut crew 
on a space mission. Because of this high risk, determining the 
probability of AF was deemed to be necessary to help keep 
astronauts safe. Incidence rates from the astronaut corps 
(Ref. 11, personal communication) and the general population 
(Ref. 12) were used to determine this probability. A Bayesian 
update was used to combine these data to yield a probability 
distribution for AF incidence. 
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2.3.1 Data and Methods 
The average rate of AF incidence in the general population 
used in this probability estimate came from an article in the 
journal Circulation (Ref. 12). These data were gathered from a 
cohort of patients at the Mayo Clinic in Olmsted County, 
Minnesota, from 1980 to 2000. An AF event was included if it 
was the first event for a particular patient and was verified by 
an electrocardiogram. These data were separated by age and 
year. In an attempt to closely approximate the current astro-
naut population, the most recent data from 1995 to 2000 for 
males and females under 55 were used. Data included the 
95-percent CI for males, females, and the total from 1995 to 
2000. However, these data were not specific to age, but were for 
all ages from 1995 to 2000. It was assumed that the 95-percent 
CI for all ages could be used as the 95-percent CI for those 
under 55. Appendix B, Section B.2, provides the steps for 
calculating the EF. All data were supplied as incidences per 
1000 person-years. Table 11 gives the average AF incidence per 
person-year for men, women, and total, along with the EFs. 
Incidences of AF in the astronaut corps and the number of 
person-years for preflight and in-flight astronauts were 
obtained from LSAH (see Table 12). There were no cases of 
AF in females during any point in the study. 
2.3.2 Bayesian Updates To Improve Estimates of Atrial 
Fibrillation Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the AF incidence rate in the astronaut corps to 
find an approximation suitable for the IMM effort. Two steps 
and Bayesian updates were performed. The first step used 
the general population data (Ref. 12) as priors to update the 
LSAH preflight data (Ref. 11, personal communication). 
This step was performed three times, once each for males, 
females, and the total. The posterior results from this step 
describe the AF incidence rate for preflight astronauts. In the 
second step, the data from these posterior results, namely the 
means and the 5th and 95th percentiles, were then used as 
the priors to update the in-flight astronaut data for males, 
females, and the total. Ultimately, six probability distribu-
tions were found describing the AF incidence rate for 
preflight and in-flight male, female, and total astronauts. 
Appendix C shows the code used in WinBUGS, and an 
outline of the input data for each step follows. 
Step 1: For females, males, and the total, the AF incidence 
per person-year in the general U.S. population (Table 11) and 
the EF were used for the priors in WinBUGS to update the 
number of AF cases for male and female astronauts from 
LSAH data (Table 12). Table 13 gives the posterior data from 
this step. 
Step 2: The posterior results from Step 1—the means and 
the 5th and the 95th percentiles (Table 13) were used as the 
priors in WinBUGS to update the in-flight astronaut data 
from LSAH (Table 12). Table 14 shows the posterior results 
of this Bayesian update: a Poisson probability distribution 
for the means, 5th and 95th percentiles, and standard devia-
tions of the AF incidence rate of in-flight astronauts.  
 
TABLE 11.—INCIDENCE OF ATRIAL FIBRILLATION (AF) IN U.S. ADULTS 
Statistic Males Females Total 
AF incidence in adults under 55 years of age 
per 1000 person-years 0.64 0.21 0.425 
95-percent confidence interval (CI) for AF 
incidence in adults per 1000 person-years 0.32 to 0.96 0.01 to 0.41 0.24 to 0.60 
AF incidence rate in adults under 55 years of 
age, events per person-year 6.40×10–4 2.10×10–4 4.25×10–4 
Error factor (EF) for AF incidence in adults 
under 55 years of age 1.56 2.97 1.45 
 
 
TABLE 12.—INCIDENCE OF ATRIAL FIBRILLATION (AF) IN PREFLIGHT  
AND IN-FLIGHT MISSION-READY, ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 6502.7 336.8 6839.5 
AF cases 4 0 4 
AF incidence rate, events per person-year 6.15×10–4 0 5.85×10–4 
In-flight astronauts 
Total person-years 31.8 6.5 38.3 
AF cases 0 0 0 
AF incidence rate, events per person-year 0 0 0 
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TABLE 13.—RESULTS OF BAYESIAN ANALYSIS  
FOR ATRIAL FIBRILLATION (AF) IN PREFLIGHT 
MISSION-READY, ACTIVE MALE, FEMALE,  
AND TOTAL ASTRONAUTS 
AF incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 6.29×10–4 2.02×10–4 4.43×10–4 
Standard deviation 1.51×10–4 1.46×10–4 9.39×10–5 
5 percent 4.12×10–4 5.60×10–5 3.06×10–4 
95 percent 9.02×10–4 4.76×10–4 6.11×10–4 
 
TABLE 14.—RESULTS OF BAYESIAN ANALYSIS FOR 
ATRIAL FIBRILLATION (AF) IN IN-FLIGHT MALE, 
FEMALE, AND TOTAL ASTRONAUTS 
AF incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 6.28×10–4 2.02×10–4 4.42×10–4 
Standard deviation 1.52×10–4 9.99×10–6 9.36×10–5 
5 percent 4.12×10–4 1.86×10–4 3.06×10–4 
95 percent 9.05×10–4 2.19×10–4 6.09×10–4 
 
2.3.3 Discussion 
These results are limited because they assume an average 
AF incidence rate and do not include specific data for ethnic-
ity, previous cardiac diseases, or health. Also, assumptions 
were made when non-age-specific 95-percent CI were used for 
age-specific data. Understanding these limitations is necessary 
in applying these results. In spite of this limitation, the 
assumptions, and the data available, Table 13 and Table 14 
present a reasonable approximation of AF incidence. These 
results can serve as a baseline for future studies that include 
further investigations into the causes of AF and more data and 
risk parameters for AF. 
2.4 Atrial Flutter 
Although atrial flutter (AFL) is less prevalent than AF, both 
are characterized by rapid atrial contractions. In contrast to 
AF, the quick AFL contractions are conducted in a regular 
pattern relative to ventricular contractions. Like AF, AFL is 
not immediately life threatening, though it can raise the 
chance of stroke. In addition, both atrial arrhythmias have 
similar debilitating symptoms, and both conditions could 
threaten the success of an astronaut if they were to occur in 
space. So that the proper amount of medications can be on 
hand for future in-flight AFL cases, the probability of AFL 
must be determined. A Bayesian update was used to combine 
experimental data from AFL incidence rates from the astro-
naut corps (Ref. 11, personal communication) and prior AFL 
incidence data from the general population (Ref. 13) to find 
this probability. 
2.4.1 Data and Methods 
The general population data describing the rate of AFL used 
in this probabilistic calculation came from Granada et al. 
(Ref. 13). This study examined the rate of AFL from the 
Marshfield Epidemiologic Study Area in Wisconsin from 
1991 to 1995. AFL cases were confirmed with electrocardio-
grams, using the International Classification of Disease code 
ICD 427.32 to define AFL. To approximate the age of the 
astronaut corps, the data recorded for men, women, and the 
total under the age of 50 were used. Included with these data 
were the 95-percent CI for men, women, and the total. These 
95-percent CI were not specific to age, however, so they were 
too wide to be applied directly to the data for adults less than 
50 years of age. Ratios between the number of AFL cases and 
95-percent CI width of all ages versus the incidence rates and 
95-percent CI width for those under 50 were used to find a 
new 95-percent CI width for adults under 50 years of age. 
Appendix B, Section B.3, gives the steps for this calculation as 
well as for the calculation of the 95-percent CI into the EF. 
These data gave the number of incidences and the number of 
person-years for males, females, and the total. Table 15 gives 
the calculated incidence rates and the corresponding EFs. 
AFL incidence data for the astronaut corps were supplied  
by LSAH (Ref. 11, personal communication). The number of 
AFL cases and person-years were included for in-flight and 
preflight male, female, and total astronauts, as shown in  
Table 16. 
2.4.2 Bayesian Updates To Improve Estimates of Atrial 
Flutter Incidence, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the AFL incidence rate in the astronaut corps 
and provide an approximation suitable for the IMM effort. 
This process took two steps. The first step was to update in 
WinBUGS the AFL incidence rate data for preflight astronauts 
performed three times, once each for males, females, and the 
total. The posterior results from the first step, including the 
means and the 5th and 95th percentiles, were used as the 
priors for another Bayesian update to the in-flight astronaut 
data. This was performed three times (once each for males, 
females, and the total) and yielded the Poisson probability 
distribution curves for the likelihood of an AFL occurrence in 
space. After these two steps, six Bayesian updates were 
performed with WinBUGS: for preflight and in-flight male, 
female, and total astronauts. Appendix C provides the  
WinBUGS code that was used, and an outline of each step, 
including the data used, follows. 
Step 1: The general population incidence rates and EFs for 
males, females, and the total (Table 15) were used as the 
priors for a Bayesian update with WinBUGS on the number of 
cases and person-years for preflight astronauts from LSAH 
(Table 16). Table 17 shows the posterior results from 
this step. 
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TABLE 15.—INCIDENCE OF ATRIAL FLUTTER (AFL)  
IN U.S. ADULTS FROM 1991 TO 1995 
Statistic Males Females Total 
AFL cases in adults under 
50 years of age 6 2 8 
Number of person-years in  
the study 84 915 82 250 167 165 
95-percent confidence interval 
(CI) for AFL in adults per 
100 000 person-years ±0.24 ±0.14 ±0.13 
AFL incidence rate for adults 
under 50 years of age per 
person-year 7.07×10–5 2.43×10–5 4.79×10–5 
Recalculated 95-percent CI for 
AFL incidence in adults per 
100 000 person-years ±0.013 ±0.004 ±0.006 
Error factor (EF) for AFL 
incidence in adults under 
55 years of age 1.17 1.18 1.11 
 
TABLE 16.—INCIDENCE OF ATRIAL FLUTTER (AFL) IN 
PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 6502.7 336.8 6839.4 
AFL cases 0 0 0 
AFL incidence rate, events per 
person-year 0 0 0 
In-flight astronauts 
Total person-years 31.8 6.5 38.3 
AFL cases 0 0 0 
AFL incidence rate , events per 
person-year 0 0 0 
 
TABLE 17.—RESULTS OF BAYESIAN ANALYSIS FOR 
ATRIAL FLUTTER (AFL) IN PREFLIGHT MISSION-READY, 
ACTIVE MALE, FEMALE, AND TOTAL ASTRONAUTS 
AFL incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 7.05×10–5 2.43×10–5 4.77×10–5 
Standard deviation 6.71×10–6 2.45×10–6 3.04×10–6 
5 percent 6.00×10–5 2.05×10–5 4.29×10–5 
95 percent 8.21×10–5 2.85×10–5 5.29×10–5 
 
TABLE 18.—RESULTS OF BAYESIAN ANALYSIS FOR 
ATRIAL FLUTTER (AFL) IN IN-FLIGHT MALE,  
FEMALE, AND TOTAL ASTRONAUTS 
AFL incidence rate, λastronaut¸ events per person-year 
Statistic Males Females Total 
Mean 7.05×10–5 2.43×10–5 4.77×10–5 
Standard deviation 6.74×10–6 2.42×10–6 3.04×10–6 
5 percent 6.00×10–5 2.05×10–5 4.29×10–5 
95 percent 8.21×10–5 2.84×10–5 5.29×10–5 
Step 2: This step used WinBUGS to combine the posterior 
results from Step 1—the means and the 5th and 95th percen-
tiles (Table 17)—with the in-flight astronaut data from Table 16. 
The result of this Bayesian update was the Poisson probability 
distribution for the AFL incidence rate in in-flight male, 
female, and total astronauts. Table 18 shows the means, the 
5th and 95th percentiles, and the standard deviations. 
2.4.3 Discussion 
Like the AF analysis, this analysis is also limited because it 
assumes an average incidence rate of AFL. There are no 
specific data for important risk factors such as ethnicity or 
previous cardiac diseases and health. Also assumptions were 
made when non-age-specific 95-percent CI were used for age-
specific data. These limitations should be kept in mind when 
this analysis is used. Despite the limitations, however, this 
analysis is a reasonable approximation of AFL incidence and 
can serve as a baseline until further investigations into the risk 
parameters and causes of AFL are made.  
2.5 Dental Abscess 
Because a dental abscess may greatly affect crewmember 
performance, health, and morale, evaluating the probability 
that an astronaut may encounter a dental abscess during an 
exploration mission was deemed to be necessary. An abscess 
results from the infection of pulp material in the tooth caused 
by complications such as decayed, cracked, or broken teeth 
(Ref. 14). U.S. Submarine Force (Ref. 15) and astronaut data 
from LSAH (Ref. 16, personal communication) were used to 
estimate the probability of an astronaut encountering dental 
abscess. The submarine crew data analysis defined periapical 
abscesses as 2010 ICD–9–CM code 522 (pulp and periapical), 
and the astronaut data from LSAH defined dental abscess as 
“abscess diagnosis,” with no reference to ICD–9 coding. A 
Bayesian update was used to combine information from these 
sources to estimate the average incidence rate of abscess.  
2.5.1 Data and Methods 
Submarine force data were used because of the physiologi-
cal similarity of the U.S. Submarine Force to astronauts. 
Deutsch (Ref. 15) conducted studies from 1997 to 2000 on the 
incidence of various dental emergencies in U.S. Submarine 
Force personnel. The medical history of submarine missions 
was useful for this statistical analysis because of their similari-
ties to exploration-class missions. For example, both occur in 
confined, remotely located environments where professional 
medical care is not immediately available. Also, a medical 
event of low probability and high consequence could cause a 
mission to cease (Refs. 17 and 18). Although there are 
similarities between a submarine mission and a space explora-
tion mission, it is important to note that smoking was  
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TABLE 19.—INCIDENCE OF DENTAL ABSCESS IN  
240 PATROLS OF THE U.S. SUBMARINE FORCE 
Total person-years ................................................................ 5946.9 
Total visits due to abscess ........................................................... 21 
Abscess incidence rate, events per person-year................3.53×10–3 
95-percent confidence interval (CI) ............................. 0.69 to 3.80 
Error factor (EF) ...................................................................... 1.48 
 
TABLE 20.—INCIDENCE OF DENTAL ABSCESS IN 
PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE MALE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Preflight astronauts 
Total person-years ................................................................... 475.2 
Number of crewmembers .............................................................77 
Abscess cases  ..............................................................................19 
Abscess incidence rate, events per person-year ................. 4.0×10–2 
In-flight astronauts 
Total person-years ..................................................................... 31.9 
Abscess cases ................................................................................ 0 
Abscess incidence rate, events per person-year ............................ 0 
 
TABLE 21.—RESULTS OF BAYESIAN ANALYSIS 
FOR DENTAL ABSCESS IN PREFLIGHT MISSION-
READY, ACTIVE MALE ASTRONAUTS 
Abscess incidence rate, λastronaut, events per person-year 
Mean 8.26×10–3 
Standard deviation 1.80×10–3 
5 percent 5.64×10–3 
Median 8.09×10–3 
95 percent 1.15×10–2 
 
TABLE 22.—RESULTS OF BAYESIAN ANALYSIS 
FOR DENTAL ABSCESS IN IN-FLIGHT  
MALE ASTRONAUTS 
Abscess incidence rate, λastronaut, events per person-year 
Mean 8.16×10–3 
Standard deviation 1.80×10–3 
5 percent 5.58×10–3 
Median 7.98×10–3 
95 percent 1.14×10–2 
 
significantly associated with the occurrence of a periodontal-
related emergency and also with the occurrence of any dental 
emergency. There is probably a greater percentage of smokers 
among the U.S. Submarine Force than among astronauts. In 
addition, the submarine study is limited in that it applies only to 
adult men and that the overwhelming majority (88.5 percent) of 
the sailors followed in this study were Caucasian. In addition, 
submarine crew members are generally more senior than the 
average sailor (70.5 percent were 25 years old or older). 
Table 19 shows the submarine crew data. The EF was deter-
mined from the 95-percent CI as outlined in Appendix B, 
Section B.4.  
Table 20 shows the LSAH dental abscess data for the astro-
naut corps from LSAH (Ref. 16, personal communication). 
For this analysis, data for the mission-ready, active female 
astronaut population was not used because the U.S. Submarine 
Force data used in the Bayesian update was for males only.  
2.5.2 Bayesian Updates To Improve Estimates of Dental 
Abscess Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of dental abscess in the 
astronaut corps and provide a first-order approximation 
suitable for the IMM effort. One Bayesian update was per-
formed using data for the U.S. Submarine Force and for 
mission-ready, active male astronauts. The submarine crew 
data were used to form an informed lognormal conjugate prior 
for the incidence rate of dental abscess in the U.S. Submarine 
Force and data on preflight incidences in male astronauts, 
yielding an updated incidence rate of abscess. In Step 3, the 
posterior result of Step 1 was used as the prior and was 
updated in WinBUGS with LSAH in-flight data. The result 
was an estimate of the incidence rate of abscess in astronauts 
during an exploration mission. Appendix C provides the code 
used in WinBUGS as well as the sampling procedure.  
Step 1: WinBUGS was informed with the mean abscess 
incidence rate for the U.S. Submarine Force and the EF from 
Table 19.  
Step 2: A Bayesian update was performed with 75 000 Monte 
Carlo samplings on the number of events and person-years for 
preflight male astronauts from LSAH data (Table 20).  
Step 3: The mean incidence rate for preflight astronauts 
from Step 1 (Table 21) was used as the prior for the second 
update, and the EF was calculated as 1.43 from the 95th and 
5th percentiles from Step 1. 
Step 4: A second Bayesian update was performed with 
75 000 Monte Carlo samples on the input parameters of 
Step 3: the number of events and person-years for in-flight 
male astronauts (Table 20). Appendix C provides details. 
This process returned an estimate of the incidence rate of 
dental abscess in the astronaut corps (λastronaut) with respect to 
the U.S. Submarine Force. This can be used as the input rate to 
a Poisson distribution to estimate the probability of abscess 
occurring during flight. Table 22 illustrates the results of the 
implementation. 
2.5.3 Discussion 
The number of events per person-years for the submarine 
population (Table 19) is 3.53×10–3 versus 8.16×10–3 for male 
astronauts (Table 22). In both submarine and astronaut data, 
there may be cases of underreporting. Astronaut health is 
typically tracked through annual physicals, where questions 
related to dental health may or may not be asked. There may 
be demographic differences between the submarine and 
astronaut data, including rates of smoking, age differences, 
and racial differences. The age difference may be important 
to note because recommended preventative dental practices 
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tend to evolve over time. Current recommended dental 
practices include daily flossing, brushing teeth twice a day for 
at least 2 minutes, seeing a dentist twice a year, and drinking 
fluoridated water (the number of communities in the United 
States with fluoridated water grows each year) (Refs. 19 
to 22). The differences between population demographics and 
access to fluoridated water may lead to discrepancies in 
incidence rates. Also, because women do not serve as subma-
rine crewmembers, female astronaut data were not used in 
this Bayesian calculation. Future analyses should include data 
for women. 
2.6 Dental Caries 
Because dental caries may greatly affect crewmember 
performance, health, and morale, evaluating the probability 
that an astronaut may encounter dental caries during an 
exploration mission was deemed to be necessary. Caries are 
caused by certain bacteria in the oral flora that release acid as 
a byproduct of carbohydrate metabolism. The acid dissolves 
the calcium phosphate of the enamel and dentin (Refs. 20 
and 21). U.S. Submarine Force data (Ref. 15) and astronaut 
data from LSAH (Ref. 16, personal communication) were 
used to estimate the probability of an astronaut encountering 
dental caries. The submarine crew data defined dental caries 
as 2010 ICD–9–CM code 521 (hard tissues and caries), and 
the astronaut data from LSAH defined dental caries as 
“primary caries, secondary caries, or order unknown,” with 
no reference to ICD–9 coding. For this analysis, the sum of 
all three caries categories was used for astronauts. A Bayesian 
update was used to combine the information from these 
sources to estimate the average rate of caries.  
2.6.1 Data and Methods 
The medical history of submarine missions was useful 
because they are similar to exploration-class missions. For 
example, both occur in confined, remotely located environ-
ments where professional medical care is not immediately 
available. Also, a medical event of low probability and high 
consequence could cause a mission to cease (Refs. 17 and 
18). It is important to note that smoking was significantly 
associated with the occurrence of a periodontal-related 
emergency and also with the occurrence of any dental 
emergency. It is likely that there is a greater percentage of 
smokers among sailors than among the astronaut corps. This 
study is limited in that it included only adult men and that 
the overwhelming majority (88.5 percent) of these men were 
Caucasian. In addition, submarine crew members are 
generally more senior than the average sailor (70.5 percent 
were 25 years old or older). Table 23 shows the submarine 
crew data. The EF was determined from the 95-percent CI as 
outlined in Appendix B, Section B.4. 
 
 
TABLE 23.—INCIDENCE OF DENTAL CARIES IN  
240 PATROLS OF THE U.S. SUBMARINE FORCE 
Total person-years ......................................................... 5946.9 
Total visits due to caries ....................................................... 29 
Caries incidence rate, events per person-year ........... 4.88×10–3 
95-percent confidence interval (CI) ......................... 0.3 to 1.53 
Error factor (EF) ................................................................ 1.11 
 
 
TABLE 24.—INCIDENCE OF DENTAL CARIES IN 
PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE MALE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Preflight astronauts 
Total person-years ........................................................... 475.2 
Number of crewmembers ..................................................... 77 
Caries cases ........................................................................ 168 
Caries incidence rate, events per person-year ........... 3.54×10–1 
In-flight astronauts 
Total person-years ............................................................. 31.9 
Caries cases ............................................................................ 0 
Caries incidence rate, events per person-year ......................... 0 
 
 
Table 24 shows the data from LSAH (Ref. 16, personal 
communication). For this analysis, data for the mission-ready, 
active female astronaut population was not used because the 
U.S. Submarine Force data only included males.  
2.6.2 Bayesian Updates To Improve Estimates of Dental 
Caries Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of dental caries in the 
astronaut corps and provide a first-order approximation 
suitable for the IMM effort. One Bayesian update was done 
using data for the U.S. Submarine Force and for mission-
ready, active male astronauts. The submarine crew data were 
used to form an informed lognormal conjugate prior for the 
incidence rate of dental caries in U.S. Submarine Force 
personnel as well as for preflight incidences in male astro-
nauts, yielding a posterior result for the updated incidence rate 
of caries. In Step 3, the posterior result of Step 1 was used as 
the prior, and updated LSAH in-flight data were used in 
WinBUGS. The result was an estimate for the incidence rate 
of abscess in astronauts during an exploration mission  
(Table 24). Appendix C shows the code used in WinBUGS as 
well as the sampling procedure.  
Step 1: WinBUGS was informed with the U.S. Submarine 
Force mean incidence rate and the EF from Table 23. 
Step 2: A Bayesian update was performed with 75 000 
Monte Carlo samplings on the number of events and person-
years for preflight male astronauts from LSAH data  
(Table 24). Table 25 shows the results.  
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TABLE 25.—RESULTS OF BAYESIAN ANALYSIS 
FOR DENTAL CARIES IN PREFLIGHT MISSION-
READY, ACTIVE MALE ASTRONAUTS 
Caries incidence rate, λastronaut, events per person-year 
Mean 9.42×10–3 
Standard deviation 5.94×10–4 
5 percent 8.48×10–3 
Median 9.40×10–3 
95 percent 1.04×10–2 
 
 
TABLE 26.—RESULTS OF BAYESIAN ANALYSIS 
FOR DENTAL CARIES IN IN-FLIGHT MISSION-
READY, ACTIVE MALE ASTRONAUTS 
Caries incidence rate, λastronaut, events per person-year 
Mean 9.41×10–3 
Standard deviation 5.95×10–4 
5 percent 8.46×10–3 
Median 9.39×10–3 
95 percent 1.04×10–2 
 
 
Step 3: The mean incidence rate from Step 1 (Table 25) was 
used as the prior for the second update, and the EF was calcu-
lated as 1.11 from the 95th and 5th percentiles from Step 1. 
Step 4: A second Bayesian update was performed with 
75 000 Monte Carlo samples on the input parameters of Step 3: 
the number of in-flight events and person-years for in-flight 
male astronauts from LSAH data (Table 24). Appendix B, 
Section B.4, provides details. 
This process returned an estimate of the incidence rate of 
dental caries in the astronaut corps (λastronaut) with respect to 
the U.S. Submarine Force. This incidence rate was used as 
input to a Poisson distribution to estimate the probability of 
caries occurring during flight. Table 26 shows the results. 
2.6.3 Discussion 
The number of dental caries events per person-year was 
4.88×10–3 in the U.S. Submarine Force versus 9.41×10–3 for 
male astronauts. In both the submarine crew and astronaut 
data, there may be cases of underreporting. Astronaut health is 
typically tracked through annual physicals, where questions 
related to dental health may or may not be asked. There may 
be demographic differences between the submarine crew and 
astronaut data, including rates of smoking, age differences, 
and racial differences. The age difference may be important to 
note because recommended preventative dental practices tend 
to evolve over time, as described in Section 2.5.3 and in 
References 17 to 21. The differences between population 
demographics and access to fluoridated water may have 
produced discrepancies in incidence rates. Also, because 
women do not serve as submarine crewmembers, female 
astronaut data were not used in this Bayesian calculation. 
Future analyses should include data for women. 
2.7 Dental Periodontal Disease 
Because periodontal disease may greatly affect crewmember 
performance, health, and morale, evaluating the probability 
that an astronaut may develop periodontal disease during an 
exploration mission was deemed to be necessary. Periodontal 
disease involves inflammation and infection that destroy the 
tissues that support the teeth, including the gums, the 
periodontal ligaments, and the tooth sockets (alveolar bone) 
(Ref. 22). Gingivitis is a form of periodontal disease due to the 
long-term effects of plaque deposits. U.S. Submarine Force 
data (Ref. 15) and astronaut data from LSAH (Ref. 16, 
personal communication) were used to estimate the probability 
of an astronaut encountering periodontal disease. The subma-
rine crew data defined periodontal disease as 2010 ICD–9–
CM code 523 (gingival and periodontal disease), and LSAH 
defined periodontal disease as “periodontal disease diagnosis,” 
with no reference to ICD–9 coding. A Bayesian update was 
used to combine information from these sources to estimate 
the average rate of periodontal disease.  
2.7.1 Data and Methods 
The medical history of submarine missions was useful for 
this statistical analysis because these missions are similar to 
exploration-class missions: both occur in confined, remotely 
located environments where professional medical care is not 
immediately available. Also, a medical event of low proba-
bility and high consequence could cause a mission to fail 
(Refs. 17 and 18). Data from Deutsch (Ref. 15) regarding the 
incidence of periodontal disease and gingivitis in the U.S. 
Submarine Force were used because of these similarities (see 
Table 27). However, it is important to note that smoking was 
significantly associated with the occurrence of a periodontal-
related emergency as it was with the occurrence of any dental 
emergency. The percentage of smokers among sailors is 
probably greater than among the astronaut corps. The U.S. 
Submarine Force study is limited in that it applies only to 
adult men, and the overwhelming majority (88.5 percent) of 
these men were Caucasian. In addition, submarine crew 
members are generally more senior than the average sailor 
(70.5 percent were 25 years old or older). Table 27 shows the 
results, where the EF was determined from the 95-percent CI 
as outlined in Appendix B, Section B.4. 
The IMM team obtained data regarding the incidence of 
periodontal disease in the astronaut corps from LSAH (Ref. 16, 
personal communication) (see Table 28). Because the U.S. 
Submarine Force data used in this Bayesian update was for 
males only, data for the mission-ready, active female astronaut 
population were not used. 
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TABLE 27.—INCIDENCE OF GINGIVAL AND 
PERIODONTAL DISEASE IN 240 PATROLS  
OF THE U.S. SUBMARINE FORCE 
Total person-years ............................................... 5946.9 
Total visits due to periodontal disease ........................ 10 
Periodontal disease incidence rate,  
events per person-year .................................. 1.68×10–3 
95-percent confidence interval (CI) ............. 0.33 to 4.19 
Error factor (EF) ...................................................... 6.24 
 
 
TABLE 28.—INCIDENCE OF PERIODONTAL DISEASE  
IN PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE MALE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Preflight astronauts 
Total person-years ......................................................................... 475.2 
Number of crewmembers ................................................................... 77 
Periodontal disease cases ................................................................... 56 
Periodontal disease incidence rate, events per person-year .... 1.18×10–1 
In-flight astronauts 
Total person-years ........................................................................... 31.9 
Periodontal disease cases ..................................................................... 0 
Periodontal disease incidence rate, events per person-year .................. 0 
2.7.2 Bayesian Updates To Improve Estimates of  
Periodontal Disease Incidence Rates, and  
Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of periodontal disease in the 
astronaut corps and provide a first-order approximation 
suitable for the IMM effort. One Bayesian update was per-
formed using U.S. Submarine Force data and data for mission-
ready, active male astronauts. The submarine crew data were 
used to form an informed lognormal conjugate prior for the 
incidence rate of periodontal disease in U.S. Submarine Force 
personnel and male astronauts, yielding a posterior result of 
the updated incidence rate of periodontal disease. In Step 3, 
the posterior result of Step 1 was used as the prior and was 
updated with LSAH in-flight data in WinBUGS. The result 
was an estimation of the incidence rate of periodontal disease 
in astronauts during an exploration mission. Appendix C 
provides the code used in WinBUGS as well as the sampling 
procedure.  
Step 1: WinBUGS was informed with the U.S. Submarine 
Force mean incidence rate and the EF from Table 27.  
Step 2: A Bayesian update was performed with 75 000 Monte 
Carlo samplings on the number of events and person-years for 
preflight male astronauts from LSAH data (Table 28).  
Step 3: The mean incidence rate for preflight astronauts 
from Step 1 (Table 29) was used as the prior for the second 
update, and the 95th and 5th percentiles from Step 1 were used 
to calculate the EF. 
 
 
TABLE 29.—RESULTS OF BAYESIAN ANALYSIS FOR 
PERIODONTAL DISEASE IN TOTAL PREFLIGHT  
MISSION-READY, ACTIVE MALE ASTRONAUTS 
Periodontal disease incidence rate, λastronaut, events per person-year 
Mean 1.10×10–1 
Standard deviation 1.52×10–2 
5 percent 8.62×10–2 
Median 1.09×10–1 
95 percent 1.36×10–1 
 
 
 
TABLE 30.—RESULTS OF BAYESIAN ANALYSIS  
FOR PERIODONTAL DISEASE IN IN-FLIGHT  
MALE ASTRONAUTS 
Periodontal disease incidence rate, λastronaut, events per person-year 
Mean 1.03×10–1 
Standard deviation 1.41×10–2 
5 percent 8.16×10–2 
Median 1.02×10–1 
95 percent 1.28×10–1 
 
 
Step 4: A second Bayesian update was performed with 
75 000 Monte Carlo samples on the input parameters of 
Step 3: the number of events and person-years for in-flight 
male astronauts from LSAH data (Table 28). Appendix C 
provides details. 
This process returned an estimate of the incidence rate of 
periodontal disease in the astronaut corps (λastronaut) with 
respect to the U.S. Submarine Force (Table 30). This rate can 
be used as the input rate to a Poisson distribution to estimate 
the probability of periodontal disease occurring during 
flight.  
2.7.3 Discussion 
The number of periodontal disease events per person-year in 
the submarine population is 2 orders of magnitude less than that 
of the male astronauts. In both the submarine and astronaut data, 
there may be cases of underreporting. Astronaut health is 
typically tracked through annual physicals, where questions 
related to dental health may or may not be asked. In addition, 
there may be demographic differences between the submarine 
crew and astronaut data, including rates of smoking, age, and 
race. The age difference may be important to note because 
recommended preventative dental practices tend to evolve over 
time, as described in Section 2.5.3 and References 19 to 22. 
These differences and differences in access to fluoridated water 
may lead to discrepancies in incidence rates. Also, because 
women do not serve as submarine crewmembers, female astro-
naut data were not used in this Bayesian calculation. Future 
analyses should include data for women. 
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2.8 Gallstone Disease 
The presence of cholesterol stones or bile pigment-based 
stones in the gallbladder is a relatively common condition that 
can lead to a variety of serious complications. Risk factors for 
gallstone disease include age, obesity, diabetes mellitus, 
pregnancy, and alcohol use. In addition, during the reproduc-
tive years, the condition is about 4 times more likely in 
women than in men. This gender discrepancy diminishes with 
age. Although gallstones may be asymptomatic, the complica-
tions of symptomatic gallstone, or biliary disease may have a 
negative impact on crewmember health, morale, and perfor-
mance. The current standard treatment for most complications 
of biliary disease is cholecystectomy, or surgical removal of 
the gallbladder (Ref. 23). Three of the severe complications of 
gallstone disease are acute cholecystitis, acute biliary pancrea-
titis, and acute cholangitis. Acute cholecystitis, or inflamma-
tion of the gallbladder, can lead to progressive pain, fever, and 
possible necrosis of the gallbladder. Treatment requires 
antibiotics and early surgical intervention (Ref. 23). Biliary 
pancreatitis occurs when a gallstone passes into and through 
the common bile duct, leading to abdominal pain and potential 
inflammation. Treatment for this condition includes endoscop-
ic removal of the stone and cholecystectomy (Ref. 23). 
Cholangitis is the infection of an obstructed bile duct, causing 
pain and fever (Ref. 24). Owing to the debilitating symptoms 
of these conditions and the difficulties that surgical treatment 
requirements pose for space exploration missions, calculating 
the incidence rate of severe gallstone disease in astronauts was 
deemed to be necessary. A Bayesian update was used to 
combine the incidence rates of acute cholecystitis, biliary 
pancreatitis, and cholangitis from a general population study 
with data on the incidence of severe gallstone disease in the 
astronaut corps from LSAH to yield a probability distribution 
describing the incidence rate of severe gallstone disease in 
astronauts (Ref. 6, personal communication). 
2.8.1 Data and Methods 
So that a first-order estimate of the incidence rate of severe 
gallstone disease in the astronaut and general populations 
could be obtained, the assumption was first made that gall-
stone disease occurs at some characteristic constant rate 
(λgallstone) over the period of interest. This allowed the number 
of gallstone events to be represented as a Poisson process with 
characteristic rate λgallstone.  
The probability distribution describing this rate in the gen-
eral population was determined from a study published in the 
Canadian Medical Association Journal that used data from the 
Canadian Institute for Health Information, the Ontario Health 
Insurance Plan physicians claims database, and the Registered 
Persons Database to determine the annual incidence rates of 
acute cholecystitis, acute biliary pancreatitis, and acute 
cholangitis per 100 000 people from 1988 to 2000. The study 
determined incidence rates for the three events separately. In 
addition, incidence rates were stratified by males and females 
and by age (Ref. 6, personal communication).  
Independence of occurrence was assumed for the different 
age groups and different diseases when these incidence rates 
were combined for the Bayesian analysis (as described in 
Appendix D) to make sure that the estimate of severe gallstone 
disease incidence in the total general population would be as 
similar as possible to that in the astronaut corps. Incidences 
provided in the study for ages 18 to 44 and 45 to 64 were 
combined to estimate the incidence of severe gallstone disease 
for a general population aged 18 to 64. It was assumed that the 
distributions describing the two groups were independent. The 
incidence rates for the three separate diseases determined in 
this fashion were summed to provide an estimate of the total 
severe gallstone disease incidence, again with the assumption 
that the distributions were independent. This procedure was 
repeated for men, women, and the total.  
Appendix D provides the method used to combine incidence 
rates with the assumption of statistical independence of the age 
groups and conditions. Table 31 summarizes the incidence rates 
in the general population that were determined via this proce-
dure. The study provided 95-percent CIs for each incidence rate 
that were combined in a fashion consistent with independent 
distributions and were used to determine estimates for the 
standard error of the general population incidence rates. These 
standard error estimates were used to construct 90-percent CIs 
for the incidence rates, which were used, in turn, to calculate the 
EFs. Table 31 provides the calculated incidence rates for men, 
women, and the total, along with the EFs. Appendix B,  
Section B.5, summarizes the technique used to determine the EF 
from the 95-percent CI provided in Reference 25. 
Data concerning the incidence of severe gallstone disease in 
the astronaut corps were obtained from the LSAH (Ref. 6, 
personal communication), as summarized in Table 32. There 
were no occurrences of severe gallstone disease in in-flight 
astronauts, and there were no occurrences at any stage in 
female astronauts. The three preflight occurrences of gallstone  
 
 
TABLE 31.—CALCULATED INCIDENCE OF GALLSTONE DISEASE IN ONTARIO FROM 1988 TO 2000 
Statistic Males Females Total 
Gallstone cases in adults 18 to 64 years of age per 100 000 person-years (derived) 76.9 126.6 101.7 
90-percent confidence interval (CI) for gallstone disease occurrences (derived) 76.1 to 77.6 125.6 to 127.5 101.2 to 102.3 
Gallstone incidence in adults 18 to 64 years of age, events/person-year 7.69×10–4 1.27×10–3 1.02×10–3 
Error factor (EF) for gallstone incidence in adults 18 to 64 years of age 1.01 1.01 1.01 
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TABLE 32.—INCIDENCE OF GALLSTONE DISEASE IN 
PREFLIGHT AND IN-FLIGHT MISSION-READY,  
ACTIVE MALE AND FEMALE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 1970.4 264.8 2235.2 
Gallstone cases 3 0 3 
Gallstone incidence rate, λastronaut, 
events per person-year 1.52×10–3 0 1.34×10–3 
In-flight astronauts 
Total person-years 32.0 6.5 38.5 
Gallstone cases 0 0 0 
Gallstone incidence rate, λastronaut, 
events per person-year 0 0 0 
 
disease in men were all 3 to 6 years preflight. Table 32 shows 
the preflight and in-flight incidence rates. 
2.8.2 Bayesian Updates To Improve Estimates of 
Gallstone Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to obtain a 
first-order estimate of the incident rate of gallstone disease in 
the astronaut corps. The analysis combined information from 
the Canadian general population with available information on 
gallstone incidence in astronauts. Informed lognormal priors 
for the incidence rate of gallstone disease in the general 
population was determined from information in Urbach et al. 
(Ref. 25), as described in Appendix D. Step 1 of the Bayesian 
analysis used this prior to update the LSAH preflight data on 
gallstone disease incidence in astronauts. This resulted in 
posterior results describing the incidence rate in preflight 
astronauts. The posterior results were used as priors for the 
second step, which updated the LSAH data for gallstone 
disease incidence in in-flight astronauts. The result was a first-
order estimate of the incidence rate of severe gallstone disease 
in astronauts on a long-duration exploration-class mission. 
This procedure was performed three times, once each for 
male, female, and total astronauts. In each Bayesian update, 
75 000 update steps were used. Appendix C provides the code 
used in WinBUGS, and an outline of the input data used in 
each step follows. 
Step 1: For males, females, and the total, the general popu-
lation incidence rates and EFs were used to inform the 
lognormal priors in WinBUGS. The LSAH preflight data that 
were updated included the number of gallstone disease cases 
and the recorded number of person-years for each population. 
Table 33 shows the gallstone incidence rates for preflight 
astronauts and provides the posterior results from this step: the 
incidence of gallstone disease in male, female, and total 
preflight astronauts.  
Step 2: The posterior results from Step 1—the means and the 
5th and the 95th percentiles (Table 33)—were used as priors in 
WinBUGS to update the LSAH data for in-flight astronauts  
 
TABLE 33.—RESULTS OF BAYESIAN ANALYSIS  
FOR GALLSTONE DISEASE IN PREFLIGHT  
MISSION-READY, ACTIVE ASTRONAUTS 
Gallstone incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 7.69×10–4 1.27×10–3 1.02×10–3 
Standard deviation 4.65×10–6 7.64×10–6 6.12×10–6 
5 percent 7.62×10–4 1.25×10–3 1.01×10–3 
95 percent 7.77×10–4 1.28×10–3 1.03×10–3 
 
TABLE 34.—RESULTS OF BAYESIAN ANALYSIS FOR 
GALLSTONE DISEASE IN IN-FLIGHT ASTRONAUTS 
Gallstone incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 7.69×10–4 1.27×10–3 1.02×10–3 
Standard deviation 4.65×10–6 7.68×10–6 6.18×10–6 
5 percent 7.62×10–4 1.25×10–3 1.01×10–3 
95 percent 7.77×10–4 1.28×10–3 1.03×10–3 
 
(Table 32). This Bayesian update resulted in probability 
distributions for the incidence of gallstone disease in male, 
female, and total astronauts during spaceflight (Table 34). 
2.8.3 Discussion 
Like the other analyses presented in this study, this analysis is 
limited because it assumes a constant incidence rate for gall-
stone disease without accounting for physiological and envi-
ronmental risk factors. Future analyses should consider 
important risk factors, including age, obesity, and diet. In 
addition, assumptions of independence were made to compute a 
general gallstone disease incidence rate from the disease-
specific rates obtained from the literature, but the incidence 
rates for different conditions and age groups might not be 
wholly independent. Furthermore, this analysis uses the 
combined incidence rates of three severe complications of 
gallstone disease as an estimate of the incidence rate for total 
gallstone disease, but these three conditions alone may not 
provide a sufficiently broad consideration of the complications 
of gallstone disease. This is evident in the fact that the incidence 
rate of gallstone disease in the in-flight male astronauts 
(1.52×10–3 events/person-year) is almost twice that of the 
general male population (7.69×10–4 events/person-year in 
Ref. 25)—a counterintuitive result. In addition, minor differ-
ences may exist between the diets and lifestyles of the Ontario 
population used and the U.S. astronaut population (Ref. 25). 
However, both populations are from well-developed, industrial 
countries in similar North American temperate regions.  
Accordingly, for the present analysis it was assumed that the 
diets are similar to a high degree. Incorporation of additional 
possible complications or related conditions might improve this 
estimate. Any use of these results must account for these limit-
ations, but this analysis is “a reasonable estimate” of the 
incidence rate of gallstone-related diseases in astronauts. 
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The accuracy of this analysis could be improved if more 
data relating to the risk factors for and the physiology of 
gallstone formation and related complications were incorpo-
rated. The current results can serve as a baseline for future 
gallstone disease predictions. 
2.9 Herpes Zoster 
The first infection of the varicella-zoster virus results in 
chicken pox. Reactivation of this virus in the cranial nerve or 
the dorsal root ganglia results in a painful rash known as 
herpes zoster (HZ) (Ref. 26)—a skin disease more commonly 
known as shingles. The cause for reactivation is unknown, but 
higher incidence rates are found for the elderly, and reactiva-
tion is generally associated with a weakened immune sys- 
tem (Ref. 26). Because the virus lives in the nerve, HZ is  
extremely painful. The probability of HZ incidences must be 
calculated to ensure that enough medications are supplied for 
any and all shingles outbreaks during a space mission. The 
general population data used in this calculation must roughly 
match the age of active astronauts because HZ reactivation 
rates increase exponentially with age. The general population 
data used came from a 2005 article in the Journal of General 
Internal Medicine (Ref. 26). A Bayesian update was use to 
combine these data with HZ incidence data from the astronaut 
corps to yield a probability distribution describing the average 
HZ incidence rate in astronauts. 
2.9.1 Data and Methods 
For the general population data, Reference 26 pulled HZ 
incidence rates from the Medstat MarketScan database, which  
 
 
2001. Incidences of HZ were defined by the 9th revision of the 
ICD. Data included the number of HZ cases per the number of 
person-years for males, females, and the total who were 40 to 
49 years of age. These data were simplified to incidences per 
person-year for males, females, and the total. The 95-percent 
CI per 1000 person-years also is given for males, females, and 
the total for ages 40 to 49. These intervals were converted into 
the EFs for males, females, and the total. Appendix B, Sec-
tion B.6, shows the steps for these conversions, and Table 35 
shows the average HZ incidence per person-year for males, 
females, and the total, along with the corresponding EFs. 
The LSAH supplied data that describe the incidence of HZ 
and the number of person-years for preflight and in-flight 
male, female, and total astronauts (Table 36 and Refs. 27 
and 28, personal communications). 
2.9.2 Bayesian Updates To Improve Estimates of Herpes 
Zoster Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of HZ in astronauts and 
provide an approximation suitable for the IMM effort. The 
first step was to perform a Bayesian update on the preflight 
astronaut data for HZ incidence with the general population 
data from Reference 26. An update was performed for males, 
females, and the total. The posterior results from this step 
describe the incidence rate of HZ in preflight astronauts.  
The means and the 5th and 95th percentiles from this first 
step then served as the priors for the second step and were 
used to perform a Bayesian update on the in-flight astronaut 
data. The update yielded the incidence rates of HZ in in-flight  
 
 
TABLE 35.—INCIDENCE OF HERPES ZOSTER (HZ) IN U.S. ADULTS FROM 2000 TO 2001 
Statistic Males Females Total 
HZ cases in adults 40 to 49 years of age 473 740 1213 
Number of person-years in the study 190 653 228 677 419 330 
95-percent confidence interval (CI) for HZ incidence in  
adults 40 to 49 years of age per 1000 person-years 2.3 to 2.8 3.0 to 3.5 2.7 to 3.0 
HZ incidence rate in adults 40 to 49 years of age per person-year 2.5×10–3 3.2×10–3 2.9×10–3 
Error factor (EF) for HZ incidence in adults 40 to 49 years of age 1.09 1.07 1.04 
 
TABLE 36.—INCIDENCE OF HERPES ZOSTER (HZ) IN PREFLIGHT AND 
IN-FLIGHT MISSION-READY, ACTIVE ASTRONAUTS  
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 1985.9 273.1 2259.0 
HZ cases 8 0 8 
HZ incidence rate, events per person-year 4.0×10–3 0 3.5×10–3 
In-flight astronauts 
Total person-years 32.5 6.5 39.0 
HZ cases 1 0 1 
HZ incidence rate, events per person-year 3.08×10–3 0 2.56×10–3 
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TABLE 37.—RESULTS OF BAYESIAN ANALYSIS FOR 
HERPES ZOSTER (HZ) IN PREFLIGHT MISSION-READY, 
ACTIVE MALE, FEMALE, AND TOTAL ASTRONAUTS 
HZ incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 2.50×10–3 3.23×10–3 2.90×10–3 
Standard deviation 1.31×10–4 1.33×10–4 6.91×10–5 
5 percent 2.29×10–3 3.02×10–3 2.78×10–3 
95 percent 2.72×10–3 3.45×10–3 3.01×10–3 
 
 
TABLE 38.—RESULTS OF BAYESIAN ANALYSIS  
FOR HERPES ZOSTER IN IN-FLIGHT MALE,  
FEMALE, AND TOTAL ASTRONAUTS 
Herpes incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 2.51×10–3 3.23×10–3 2.90×10–3 
Standard deviation 1.31×10–4 1.30×10–4 7.04×10–5 
5 percent 2.30×10–3 3.02×10–3 2.79×10–3 
95 percent 2.73×10–3 3.45×10–3 3.02×10–3 
 
astronauts. Appendix C provides the WinBUGS code used, 
and an outline of the data for these steps follows. 
Step 1: The general population HZ incidence per person-
year for males, females, and the total and the corresponding 
EFs used as the priors in this step came from Reference 26. 
The LSAH data updated in this step included the number of 
preflight person-years and HZ incidences for males, females, 
and the total. Table 35 shows the incidence rates and the 
corresponding EFs for the general population, and Table 36 
shows the incidences for preflight astronauts. Table 37 shows 
the posterior results: Poisson probability distributions for 
males, females, and the total. 
Step 2: The means and the 5th and 95th percentiles from the 
posterior results of Step 1 (Table 37) were used as the priors 
for this step. Table 36 shows the LSAH data for in-flight 
astronauts, and Table 38 shows the posterior results from 
Step 2: the incidence of HZ in in-flight astronauts. 
2.9.3 Discussion 
Understanding the limitation of assuming an average rate 
for HZ incidence is necessary for the appropriate use of these 
data. HZ incidence rate increases exponentially with age (the 
rate for 50 to 59 year olds is double the rate for 40 to 49 year 
olds). Therefore, capturing the ages closest to the astronaut 
corps is imperative (Ref. 26). In spite of these limitations, this 
analysis is a reasonable approximation of HZ incidence. These 
data could also be used as a baseline for any future studies 
relating to HZ. 
2.10 Renal Stones 
Data from LSAH (Ref. 29, personal communication) and 
the National Institutes of Health (NIH) (Ref. 30) were used to 
estimate the probability of an astronaut developing a renal 
stone during or after space flight. A Bayesian update was used 
to combine information from these sources to estimate the 
average rate of renal stone formation. This analysis uses only 
data pertaining to renal stone occurrence, not data related to 
blood or urine chemistry. 
2.10.1 Data and Methods 
The LSAH temporal distribution of renal stone formation 
provided to the IMM team indicates that the assumptions that 
(1) the rates (λ) of renal stone incidences are constant over the 
period of interest and (2) the probability of occurrence follows 
a Poisson distribution are probably erroneous. However, the 
authors believe that these assumptions are currently the “best 
approximation” on the basis of nonattributable data from 
short-duration-mission (<20 days) participants. Only one data 
point is available for renal stone incidence during long-
duration missions (~180 days) at this time. 
Table 39 shows the general population incidence rate of 
renal stones from the NIH as of 2004 (Ref. 30). The incidence 
of renal stones differed for males and females, but for this 
analysis, the differences between males and females were not 
considered, and the average incidence rate of renal stones of 
1.8×10–3 was used. An EF of 2.236 was found by taking the 
square root of the ratio 3 to 0.6.  
The LSAH data for the astronaut population at Johnson 
were of interest because renal stone incidence is geographi-
cally dependent because of dietary habits, lifestyle, and other 
factors. The LSAH data were used to capture discrepancies 
due to geography. Table 40 shows the renal stone incidence 
data for this ground-based comparison population from 
Pietrzyk et al. (Ref. 31).  
There have been no incidences of renal stones in in-flight 
astronauts (Table 41 and Ref. 31). In Table 41, the total 
number of person-years reported includes the timeframe for 
in-flight data. 
 
TABLE 39.—INCIDENCE OF RENAL STONES IN  
THE U.S. GENERAL POPULATION AS OF 2004 
Statistic Males Females 
Renal stone cases, events per 1000 person-years 1 to 3 0.6 to 1 
Mean number of events per 1000 person-years ............................ 1.8 
Renal stone incidence rate, events per person-year ............. 1.8×10–3 
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TABLE 40.—INCIDENCE OF RENAL STONES IN THE 
ANALOG ASTRONAUT POPULATION  
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Number of participants ............................................................. 927 
Renal stone cases ........................................................................ 74 
Number of person-years .................................................... 17 740.8 
Renal stone incidence rate, events per person-year ............ 4.2×10–3 
 
 
TABLE 41.—INCIDENCE OF RENAL STONES  
IN IN-FLIGHT ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Renal stone cases .......................................................................... 0 
Number of person-years ........................................................... 25.1 
Renal stone incidence rate, events per person-year ....................... 0 
 
2.10.2 Bayesian Updates To Improve Estimates of Renal 
Stone Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the renal stone incidence rate for astronauts 
and provide a first-order approximation suitable for the IMM 
effort. One Bayesian update was performed without distin-
guishing between data for males and females. The data from 
the NIH (Ref. 30) were used to form an informed lognormal 
conjugate prior for the incidence rate of renal stones in the 
general U.S. population (λgeneral). This prior was used to update 
the LSAH astronaut data in Step 1 of the Bayesian implemen-
tation, yielding a posterior result for the updated incidence rate 
of renal stones. In Step 2, the posterior result of Step 1 was 
used as the prior to update the LSAH in-flight astronaut data 
in WinBUGS. The result was an estimation of the incidence 
rate of renal stone formation in astronauts during an explora-
tion mission. Appendix C provides the code used in  
WinBUGS as well as the sampling procedure.  
Step 1: WinBUGS was informed with the mean incidence 
rate λgeneral from Table 39 and the EF (2.236). 
Step 2: A Bayesian update was performed with 75 000 
Monte Carlo samples on the input parameters of Step 1: the 
number of events and person-years for preflight astronauts 
from Table 40. 
Step 3: The posterior result of Step 2—the mean incidence 
rate (Table 42) was dissected and used as the prior for the 
second update. The 5th and 95th percentiles from the lognor-
mal Poisson distribution in Step 2 (Table 43) were used to 
calculate the EF. 
Step 4: A second Bayesian update was performed with 
75 000 Monte Carlo samples on the input parameters of 
Step 1: the number of events and person-years for in-flight 
astronauts (Table 41).  
This process returned an estimate of the incidence rate of 
renal stone formation in in-flight astronauts with respect to the 
general population and the LSAH analog population (Table 43). 
This can be used as the input rate to a Poisson distribution to 
estimate the probability of a renal stone occurrence.  
 
TABLE 42.—RESULTS OF BAYESIAN ANALYSIS 
FOR RENAL STONES IN THE ANALOG 
ASTRONAUT POPULATION 
Renal stone incidence rate, λanalog, events per person-year 
Mean 3.97×10–3 
Standard deviation 4.58×10–4 
5 percent 3.24×10–3 
95 percent 4.74×10–3 
 
 
TABLE 43.—RESULTS OF BAYESIAN ANALYSIS 
FOR RENAL STONES IN IN-FLIGHT  
ASTRONAUTS (ESTIMATE) 
Renal stone incidence rate, λastronaut, events per person-year 
Mean 3.96×10–3 
Standard deviation 4.60×10–4 
5 percent 3.25×10–3 
95 percent 4.76×10–3 
 
2.10.3 Discussion 
This analysis should be considered limited in that it assumes 
an average incidence rate of renal stones, irrespective of the 
renal stone type or environmental conditions. The results are a 
reasonable representation of the renal stone incidence rate 
given the data available and the assumptions made during 
construction of the estimate. 
More accurate estimates could be made with further analy-
sis of differences between males and females and the urinary 
and serum chemistry values that pertain to renal stone for-
mation. The current data will serve as the baseline for future 
estimates that utilize biochemical renal stone forming and 
inhibiting parameters.  
2.11 Seizure 
Because a seizure may greatly affect crewmember perform-
ance, health, and morale, evaluating the probability that an 
astronaut may experience a seizure during an exploration 
mission was deemed to be necessary. A seizure is a major 
disruption of electrical signaling between neurons in the brain, 
and epilepsy is a disorder characterized by the recurrence of 
seizures. In normal brain function, neurons communicate with 
other neurons, glands, and muscles via electrochemical 
impulses. These neuronal impulses propagate along the axon, 
initiating the release of neurotransmitters that flow across the 
synaptic cleft to the dendrites of an adjacent cell. A balance 
between excitatory and inhibitory neurotransmitters controls 
the firing of electrical impulses. When excitatory neurotrans-
mitters exceed the threshold, an action potential results. A 
seizure is an episode of continual and uncontrolled neuronal 
firing causing convulsions, muscle contractions, and uncon-
sciousness. Seizures may be triggered by head trauma, physical 
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and emotional stress, fatigue, and external stimuli. However, 
most cases of seizure are idiopathic (Ref. 32). Data from the 
general population (Ref. 33) and astronaut data from the 
LSAH (Ref. 6, personal communication) were used to esti-
mate the probability of an astronaut experiencing a seizure. A 
Bayesian update was used to combine the incidence rates of 
seizure from these sources to yield an appropriate incidence 
rate of seizure. The rate was assumed to be constant, and a 
Poisson probability distribution was assumed to govern the 
probability of seizure. 
2.11.1 Data and Methods 
General population data for the incidence rate of a first 
unprovoked (idiopathic) seizure were obtained from a  
Rochester, Minnesota, epidemiologic project (Ref. 33). A 
seizure was defined as an abnormal and excessive discharge of 
a set of neurons in the brain. In this study, incidence rates of 
epilepsy and of all unprovoked seizures were considered. An 
idiopathic seizure is one that occurs without an identified 
cause. Of all seizures, 61 to 66 percent are idiopathic and 23 to 
35 percent are generalized tonic-clonic (Refs. 33 and 34). The 
incidence per 100 000 person-years of a first unprovoked 
seizure in adults 40 to 54 years of age was slightly higher in 
males (29) than in females (25). For this estimate, the inci-
dence rate of seizures in males and females was averaged as 
shown in Table 44. Because there is not a significant variation 
in the incidence of seizure between males and females, the 
average incidence rate was considered appropriate. The inci-
dence of seizure is related to age—incidence rates were high 
for infants younger than 1 year and highest for persons older 
than 75 years of age. CI information was not available for a 
first unprovoked seizure. Therefore, the EF was estimated 
from the 90th-percentile CI constructed from total population 
data for epilepsy. A person experiencing a single unprovoked 
seizure was not diagnosed with epilepsy and thus was not 
included in the CI data. The incidence rate of a first unpro-
voked seizure was 33 percent higher than the incidence rate of 
epilepsy, primarily because individuals who experienced only 
one unprovoked seizure were added. Data for this estimate 
were averaged from three age ranges: 40 to 44, 45 to 49, and 
50 to 54, yielding an average age of 47 years. The EF was 
estimated to be 1.19 from a 90th-percentile CI constructed 
from male and female data from a population aged 40 to 
54 years (see Appendix B, Section B.7). 
Data for the incidence of seizure in the astronaut corps were 
obtained from the LSAH (Ref. 6, personal communication), 
and are summarized in Table 45. There were no occurrences 
of seizure in in-flight astronauts. 
 
 
TABLE 44.—INCIDENCE OF TOTAL SEIZURES IN THE 
GENERAL POPULATION AGED 40 TO 54 YEARS IN 
ROCHESTER, MINNESOTA, FROM 1935 TO 1984 
Average incidence per 100 000 person-years ......................... 27 
Seizure incidence rate, events per person-year .............. 2.7×10-4 
TABLE 45.—INCIDENCE OF SEIZURES IN PREFLIGHT 
AND IN-FLIGHT MISSION-READY, ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 1970.4 264.8 2235.2 
Seizure cases 0 0 0 
Seizure incidence rate, events  
per person-year 0 0 0 
In-flight astronauts 
Total person-years 32.0 6.6 38.6 
Seizure cases 0 0 0 
Seizure incidence rate, events  
per person-year 0 0 0 
 
TABLE 46.—RESULTS OF BAYESIAN ANALYSIS 
FOR SEIZURES IN TOTAL PREFLIGHT MISSION-
READY, ACTIVE ASTRONAUTS  
Seizure incidence rate, λastronaut, events per person-year 
Mean 2.68×10-4 
Standard deviation 2.84×10-5 
5 percent 2.24×10-4 
Median 2.67×10-4 
95 percent 3.17×10-4 
 
2.11.2 Bayesian Updates To Improve Estimates of 
Seizure Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence rate of seizure in the astronaut 
corps and provide a first-order approximation suitable for the 
IMM effort. The general population data (Ref. 33) were used 
to determine an informed lognormal conjugate prior for the 
incidence rate of seizure in the general U.S. population 
(λgeneral). This prior was used to update LSAH preflight data in 
Step 1 of the Bayesian implementation, yielding a posterior 
result of the updated incidence rate of seizure. In Step 2, the 
posterior result of Step 1 was used as the prior and was 
updated with LSAH in-flight data in WinBUGS. The result 
was an estimation of the incidence rate of seizure in astronauts 
during an exploration mission. Appendix C contains the code 
used in WinBUGS as well as the sampling procedure.  
Step 1: WinBUGS was informed with the mean incidence 
rate of the general population from Table 44 and the EF. 
Step 2: A Bayesian update was performed with 75 000 
Monte Carlo samples on the input parameters of Step 1: the 
number of events and person-years for preflight astronauts 
from LSAH (Table 45). 
Step 3: The posterior result of Step 2—the mean incidence 
rate (Table 46) was dissected and used as the prior for the second 
update, and the 5th and 95th percentiles from the lognormal 
Poisson distribution in Step 2 were used to calculate the EF. 
Step 4: A second Bayesian update was performed with 
75 000 Monte Carlo samples on the input parameters of 
Step 1: the number of events and person-years for in-flight 
astronauts (Table 45). Appendix C provides details. 
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TABLE 47.—RESULTS OF BAYESIAN ANALYSIS 
FOR SEIZURES IN TOTAL IN-FLIGHT 
ASTRONAUTS 
Seizure incidence rate, λastronaut, events per person-year 
Mean 2.70×10-4 
Standard deviation 2.88×10-5 
5 percent 2.25×10-4 
Median 2.68×10-4 
95 percent 3.19×10-4 
 
 
Table 47 shows the results: an estimate of the incidence rate 
of seizure in in-flight astronauts with respect to the general 
population. This rate can be used as the input rate to a Poisson 
distribution probability to estimate the probability of seizure 
occurring in flight.  
2.11.3 Discussion 
This analysis is limited in that it assumes an average inci-
dence rate of seizure irrespective of the environmental 
conditions and the cause of seizure. In addition, the EF was 
calculated with epilepsy data, not unprovoked seizure data, 
because Reference 33 did not have CI data on the first unpro-
voked seizure. Also, data regarding repeated occurrences of 
seizures could influence the predicted rate of incidence 
because it is known that having a single seizure greatly 
increases the likelihood of subsequent seizures. The results 
should be used with an understanding of these limitations. 
However, these results probably give a reasonable representa-
tion of the incidence rate of seizures given the data available 
and the assumptions made when the estimate was constructed. 
More accurate estimates could be made with further analy-
sis of seizure occurrence in post-flight astronauts and greater 
understanding of the cause of seizures. The current analysis 
data will serve as the baseline for future estimates of the 
incidence of seizures in astronauts. 
2.12 Stroke 
Because a stroke may greatly affect crewmember perfor-
mance and health, evaluating the probability that an astronaut 
may experience a stroke during an exploration mission was 
deemed to be necessary. The most common type of stroke is 
ischemic stroke (also referred to as a cerebral infarction) 
(Ref. 35), where blood flow to the brain is blocked by blood 
clots and/or by fatty deposits called plaque in the blood vessel 
linings. According to the Centers for Disease Control (CDC), 
about 85 percent of all strokes are ischemic (Ref. 35). This 
analysis only used data pertaining to stroke incidence for ages 
similar to those of mission-ready astronauts, not data related to 
blood pressure or other physiological conditions. A Bayesian 
update was used to combine the incidence rates of stroke from 
the LSAH (Ref. 36, personal communication) and the general 
U.S. population (Ref. 37) to estimate the average rate of stroke.  
2.12.1 Data and Methods 
As of 2010, the American Heart Association (Ref. 37) gave 
the incidence rate of ischemic stroke in U.S. residents 45 to 
54 years of age as 1.1 to 2.7 per 1000 person-years for males 
and 0.7 to 2.2 per 1000 person–years for females. 
Reference 37 considers the higher incidence rates for black 
men and women (2.7 and 2.2, respectively) to be unreliable, 
although a rationale for this view is not specified. The lower 
incidence rate data are for white men and women (1.1 and 0.7, 
respectively). This Bayesian calculation only includes the data 
for whites (see Table 48), although data for black men and 
women were used in calculating the EFs: males, 1.567; 
females, 1.773; and total, 1.254. Data from this publication 
indicate that the prevalence of stroke among Hispanics and 
Latinos is higher than among whites but smaller than among 
blacks (Ref. 37). 
As of 2007 there were 101 astronauts that were mission 
ready (20 females and 81 males). The LSAH data were given 
for males and females, so data for white males, females, and 
the total were used for the general population calculation. For 
this analysis, gender, age, ethnicity, and type of stroke—
ischemic—were simplified and assumed to be lognormal, as 
shown in Table 48. 
Data received from LSAH (Ref. 36, personal communica-
tion) are given in Table 49. Of the two incidents of preflight 
stroke, one occurred 0 to 3 years prior to flight and one 
occurred 3 to 6 years prior to flight. The fact that there were 
no strokes recorded for female astronauts may negate the 
assumption of an average incidence rate for the entire period 
of interest. 
 
TABLE 48.—INCIDENCE OF STROKE IN U.S. ADULTS  
45 TO 54 YEARS OF AGE 
Statistic Males Females Total 
Stroke incidence in white 
adults aged 45 to 54 years 
per 1000 person-years 1.1 0.7 0.9 
Mean stroke incidence rate in 
adults aged 45 to 54 years, 
events per person-year 1.10×10–3 7.00×10–4 9.00×10–4 
 
TABLE 49.—INCIDENCE OF STROKE IN PREFLIGHT AND 
IN-FLIGHT MISSION-READY, ACTIVE ASTRONAUTS 
[From Lifetime Surveillance of Astronaut Health (LSAH).] 
Statistic Males Females Total 
Preflight astronauts 
Total person-years 3478.6 336.8 3815.4 
Stroke cases 2 0 2 
Stroke incidence rate, events  
per person-year 5.75×10–4 0 5.24×10–4 
In-flight astronauts 
Total person-years 31.8 6.5 38.3 
Stroke cases 0 0 0 
Stroke incidence rate, events  
per person-year 0 0 0 
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2.12.2 Bayesian Updates To Improve Estimates of Stroke 
Incidence Rates, and Analysis Results 
The following steps were taken with WinBUGS to improve 
the estimate of the incidence of stroke in astronauts and pro-
vide a first-order approximation suitable for the IMM effort. 
Two steps and Bayesian updates were performed. The first step 
used the general population data (Ref. 37) as a prior to update 
the LSAH preflight data (Ref. 36, personal communication). 
This step was performed three times, once each for males, 
females, and the total. The posterior results from this step 
describe the stroke incidence rates for preflight astronauts. In 
the second step, the data from these posterior results, namely 
the means and the 5th and 95th percentiles, were used as the 
priors to update the in-flight astronaut data for females, males, 
and the total. Ultimately, six probability distributions were 
found describing the stroke incidence rate for preflight and 
in-flight male, female, and total astronauts. Appendix C 
provides the code used in WinBUGS, and an outline of the 
input data for each step follows. 
Step 1: The stroke incidence per person-year for the general 
U.S. population for females, males, and the total and the EFs 
were used as the priors in WinBUGS to update the LSAH data 
(Table 49) for the number of stroke cases and person-years for 
males, females, and the total. Table 50 provides the posterior 
results from this step. 
Step 2: A Bayesian update was performed with the posterior 
results from Step 1—the means and the 5th and 95th percen-
tiles (Table 50) to update the LSAH in-flight astronaut data 
(Table 49). The result was a probability distribution for the 
stroke incidence rate in in-flight astronauts (Table 51). 
 
TABLE 50.—RESULTS OF BAYESIAN ANALYSIS FOR 
STROKE IN PREFLIGHT MISSION-READY, ACTIVE  
MALE, FEMALE, AND TOTAL ASTRONAUTS 
Stroke incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 9.81×10–4 6.80×10–4 8.78×10–4 
Standard deviation 2.42×10–4 2.41×10–4 1.17×10–4 
5 percent 6.37×10–4 3.64×10–4 6.99×10–4 
Median 9.54×10–4 6.42×10–4 8.70×10–4 
95 percent 1.4×10–3 1.1×10–3 1.1×10–3 
 
TABLE 51.—RESULTS OF BAYESIAN ANALYSIS FOR 
STROKE IN IN-FLIGHT MALE, FEMALE,  
AND TOTAL ASTRONAUTS 
Stroke incidence rate, λastronaut, events per person-year 
Statistic Males Females Total 
Mean 9.80×10–4 6.80×10–4 8.77×10–4 
Standard deviation 2.38×10–4 2.36×10–4 1.22×10–4 
5 percent 6.41×10–4 3.71×10–4 6.93×10–4 
Median 9.52×10–4 6.42×10–4 8.69×10–4 
95 percent 1.4×10–3 1.1×10–3 1.1×10–3 
 
2.12.3 Discussion 
This analysis is limited in that it assumes an average inci-
dence rate of stroke, with little data regarding stroke type or 
environmental conditions. Also, because the data for blacks in 
the general population were considered to be unreliable, this 
analysis only considered data from white males and females 
from the general population. These results should be used with 
a full understanding of these limitations. However, they are 
reasonable representations of the incidence rate of stroke 
given the data available and the assumptions made when the 
estimate was constructed. 
More accurate estimates could be made with further analy-
sis of stroke incidence in post-flight astronauts and the 
physiological data that pertain to stroke occurrence. If more 
reliable data for the general U.S. population (specifically for 
different ethnicities) becomes available in the future, this 
analysis should be updated with that data. The current data 
will serve as the baseline for future estimates.  
3.0 Discussion 
Tables 52 and 53 summarize the results of the Bayesian 
analyses for all medical events in preflight and in-flight 
astronauts. 
A review of the data for various medical events demon-
strates limitations that are common to all events. The analysis 
of each medical condition assumes an average incidence rate 
despite environmental effects and contributing physiological 
factors. There are certainly discrepancies between the general 
U.S. population, the U.S. Submarine Force, the analog 
astronaut population at the NASA Johnson Space Center, and 
the astronaut corps. The data reported in the literature for the 
various medical events has inherent uncertainty and reliability 
problems depending on the manner in which the study or 
survey was conducted. 
There are a host of factors that could improve the IMM 
team’s ability to make more accurate estimates of the inci-
dence rates, including incorporating biomedical parameters 
into the model and having access to more precise data (in the 
astronaut corps and in the general U.S. and submarine popula-
tions) related to age, ethnicity, gender, previous medical 
conditions, existing lifestyle choices, and so on. Having age-, 
ethnicity-, and gender-specific CI would greatly improve the 
calculation of the total incidence rates. However, given that 
these Bayesian analyses were performed to support the IMM 
by providing input source data, the intrinsic nature of this 
probabilistic model and its associated sensitivity analyses of 
output data will also guide the need for future updates. As 
components of IMM source input data, the incidence rate data 
described herein will be subject to periodic review to ensure 
that they are current and relevant as described in the IMM 
Configuration Management Plan (Ref. 38). 
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TABLE 52.—RESULTS OF BAYESIAN ANALYSIS FOR ALL 
MEDICAL EVENTS IN PREFLIGHT MISSION-READY, 
ACTIVE MALE, FEMALE, AND TOTAL ASTRONAUTS 
Medical event incidence rate, λastronaut, events per year 
Statistic Males Females Total 
Angina pectoris 
Mean 3.96×10–4 3.65×10–4 N/A 
Standard deviation 9.38×10–5 1.53×10–4 N/A 
Appendicitis 
Mean N/A N/A 9.35×10–4 
Standard deviation N/A N/A 1.04×10–4 
Atrial fibrillation (AF) 
Mean 6.29×10–4 2.02×10–4 4.43×10–4 
Standard deviation 1.51×10–4 1.46×10–4 9.39×10–5 
Atrial flutter (AFL) 
Mean 7.05×10–5 2.43×10–5 4.77×10–5 
Standard deviation 6.71×10–6 2.45×10–6 3.04×10–6 
Dental abscess 
Mean 8.26×10–3 N/A N/A 
Standard deviation 1.80×10–3 N/A N/A 
Dental caries 
Mean 9.42×10–3 N/A N/A 
Standard deviation 5.94×10–4 N/A N/A 
Dental periodontal disease 
Mean 1.10×10–1 N/A N/A 
Standard deviation 1.52×10–2 N/A N/A 
Gallstone disease 
Mean 7.69×10–4 1.27×10–3 1.02×10–3 
Standard deviation 4.65×10–6 7.64×10–6 6.12×10–6 
Herpes zoster (HZ) 
Mean 2.50×10–3 3.23×10–3 2.90×10–3 
Standard deviation 1.31×10–4 1.33×10–4 6.91×10–5 
Renal stones 
Mean N/A N/A 3.97×10–3 
Standard deviation N/A N/A 4.58×10–4 
Seizure 
Mean N/A N/A 2.68×10-4 
Standard deviation N/A N/A 2.84×10-5 
Stroke 
Mean 9.81×10–4 6.80×10–4 8.78×10–4 
Standard deviation 2.42×10–4 2.41×10–4 1.17×10–4 
 
 
Glenn Research Center 
National Aeronautics and Space Administration 
Cleveland, Ohio, June 18, 2012
 
TABLE 53.—RESULTS OF BAYESIAN ANALYSIS FOR ALL 
MEDICAL EVENTS IN IN-FLIGHT MALE, FEMALE,  
AND TOTAL ASTRONAUTS 
Medical event incidence rate, λastronaut, events per year 
Statistic Males Females Total 
Angina pectoris 
Mean 3.95×10–4 3.64×10–4 N/A 
Standard deviation 9.21×10–5 1.53×10–4 N/A 
Appendicitis 
Mean N/A N/A 9.34×10–4 
Standard deviation N/A N/A 1.03×10–4 
Atrial fibrillation (AF) 
Mean 6.28×10–4 2.02×10–4 4.42×10–4 
Standard deviation 1.52×10–4 9.99×10–6 9.36×10–5 
Atrial flutter (AFL) 
Mean 7.05×10–5 2.43×10–5 4.77×10–5 
Standard deviation 6.74×10–6 2.42×10–6 3.04×10–6 
Dental abscess 
Mean 8.16×10–3 N/A N/A 
Standard deviation 1.80×10–3 N/A N/A 
Dental caries 
Mean 9.41×10–3 N/A N/A 
Standard deviation 5.95×10–4 N/A N/A 
Dental periodontal disease 
Mean 1.03×10–1 N/A N/A 
Standard deviation 1.41×10–2 N/A N/A 
Gallstone disease 
Mean 7.69×10–4 1.27×10–3 1.02×10–3 
Standard deviation 4.65×10–6 7.68×10–6 6.18×10–6 
Herpes zoster (HZ) 
Mean 2.51×10–3 3.23×10–3 2.90×10–3 
Standard deviation 1.31×10–4 1.30×10–4 7.04×10–5 
Renal stones 
Mean N/A N/A 3.96×10–3 
Standard deviation N/A N/A 4.60×10–4 
Seizure 
Mean N/A N/A 2.70×10-4 
Standard deviation N/A N/A 2.88×10-5 
Stroke 
Mean 9.80×10–4 6.80×10–4 8.77×10–4 
Standard deviation 2.38×10–4 2.36×10–4 1.22×10–4 
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Appendix A.—Data from Lifetime Surveillance of Astronaut Health (LSAH) 
Table 54 shows the data that were supplied by LSAH. 
 
TABLE 54.—LIFETIME SURVEILLANCE OF ASTRONAUT HEALTH (LSAH) DATA 
Preflight astronauts In-flight astronauts 
Statistic Males Females Statistic Males Females 
Angina pectoris 
Total person-days 719 196 96 669 Total person-days 11 680 2372.5 
Total person-years 1970.4 264.8 Total person-years 32.0 6.5 
Angina cases 0 0 Angina cases 0 0 
Appendicitis 
Total person-days 510 875 89 019 Total person-days 11 643.5 2336 
Total person-years 1399.7 243.9 Total person-years 31.9 6.4 
Appendicitis cases 2 0 Appendicitis cases 0 0 
Atrial fibrillation (AF) 
Total person-days 2 373 481 122 915 Total person-days 11 607 2372.5 
Total person-years 6502.7 336.8 Total person-years 31.8 6.5 
AF cases 4 0 AF cases 0 0 
Atrial flutter (AFL) 
Total person-days 2 373 481 122 915 Total person-days 11 607 2372.5 
Total person-years 6502.7 336.8 Total person-years 31.8 6.5 
AFL cases 0 0 AFL cases 0 0 
All dental problems studied 
Total person-days 173 450.6 43 855.2 Total person-days 11 643.5 2336 
Total person-years 475.2 120.2 Total person-years 31.9 6.4 
Caries cases 168 24 Caries cases 0 0 
Abscess cases 19 1 Abscess cases 0 0 
Periodontal disease cases 56 9 Periodontal disease cases 0 0 
Gallstone disease 
Total person-days 719 196 96 669 Total person-days 11 680 2372.5 
Total person-years 1970.4 264.8 Total person-years 32.0 6.5 
Gallstone cases 3 0 Gallstone cases 0 0 
Herpes zoster (HZ) 
Total person-days 724 861 99 684 Total person-days 11 862.5 2372.5 
Total person-years 1985.9 273.1 Total person-years 32.5 6.5 
HZ cases 8 0 HZ cases 1 0 
Renal stonesa 
Total person-days N/A N/A Total person-days 9161.5 
Total person-years N/A N/A Total person-years 25.1 
Renal stone cases N/A N/A Renal stone cases 0 
Seizure 
Total person-days 719 196 96 669 Total person-days 11 680 2372.5 
Total person-years 1970.4 264.8 Total person-years 32.0 6.5 
Seizure cases 0 0 Seizure cases 0 0 
Stroke 
Total person-days 1 269 681 12 2915 Total person-days 11 607 2372.5 
Total person-years 3478.6 336.8 Total person-years 31.8 6.5 
Stroke cases 2 0 Stroke cases 0 0 
aTotals only—no breakdown by males and females. 
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Appendix B.—Calculating Error Factor From 95-Percent Confidence Intervals 
 
For general population data to be applicable to these  
Bayesian updates, the error factor (EF) for each data set had to 
be found. Although no data in this study gave the EF, some 
data gave the standard deviation, leading to an easy conver-
sion to the EF. However, many times the standard deviation 
was not given, so the EF had to be calculated using the 
95-percent confidence interval (CI). The general steps in-
volved converting the 95-percent CI into a 90-percent CI. 
From the 90-percent CI, the 95th and 5th percentiles were 
found and then used in a simple equation to calculate the EF. 
The specific calculation steps for each medical event varied. 
These steps are shown in Sections B.1 to B.7. 
B.1 Angina Pectoris 
The following steps were used to obtain the EF for the 
angina data: 
 
(1) The 95-percent CI width was used to find the standard 
deviation σ from Equation (B1) from Lapin’s book 
(Ref. 39): 
 
( )95%
2
widthn
zα
σ =
 (B1) 
where zα/2 is 1.96 for the 95-percent CI, n is the number 
of participants, and width95% is 1.2 for males and 0.55 
for females. 
(2) Next, Equation (B1) and σ were used to find the 
90-percent CI width: 
 
2z nα
σ
×
 = width90% (B2) 
where zα/2 = 1.64 for the 90-percent CI. The 90-percent 
CI width was calculated as 1.00 for males and 0.46 for 
females. 
(3) Then, the 95th percentile was found by adding the 
90-percent CI width to the mean, and the 5th percentile 
was found by subtracting the 90-percent CI width from 
the mean. 
The 95th percentile was calculated as 5.80 for males 
and 1.56 for females. The 5th percentile was calculated 
as 3.80 for males and 0.64 for females. 
(4) Finally Equation (B3) was used to find EF: 
  
95th
5th
EF =
 (B3) 
EF was calculated as 1.24 for males and 1.56 for  
females. 
B.2 Atrial Fibrillation 
The following steps were used to obtain the EF for atrial 
fibrillation (AF) data: 
 
(1) The 95-percent CI width was used to find σ from  
Equation (B1), where zα/2 is 1.96 and width95% is 0.32 
for males, 0.2 for females, and 0.18 for the total. 
Next Equation (B1) and σ were used to find the 
90-percent CI width—resulting in Equation (B2), 
where zα/2 = 1.64 for the 90-percent CI. 
(2) Then, the 95th percentile was found by adding the 
90-percent CI width to the mean, and the 5th percentile 
was found by subtracting the 90-percent CI width from 
the mean. 
(3) Finally, Equation (B3) was used to find EF. 
B.3 Atrial Flutter 
With the atrial flutter (AFL) data, additional steps had to be 
taken prior to converting the 95-percent CI into the 90-percent 
CI. The CIs were too wide to be applied directly to the rates of 
AFL for adults under 50 years of age because doing so would 
have created negative values for the 5th and 2.5th percentile. 
A proportion was set up to counter this problem. The propor-
tion was between the number of cases for adults under 
50 years of age and the number of cases for all ages. It was set 
equal to the proportion of the unknown 95-percent CI width x 
for adults under 50 years of age and the known 95-percent CI 
width for all ages. An example of the calculation for the 
95-percent CI for men under 50 years of age follows: 
 
AFL cases in men under 50 years
AFL cases in all men
95% CI width for men under 50 years
95% CI width for all men
=
 
 
6 AFL cases
112 AFL cases 0.24
x
=
 (B4) 
 x = ±0.011 
This assumption of proportional 95-percent CI was applied to 
the women and total adults under 50 years of age as well. The 
three calculated 95-percent CIs for adults under 50 years of 
age follow: 
 
 Men: ±0.013-percent cases per 100 000 person-years 
 Women: ±0.004-percent cases per 100 000 person-years 
 Total: ±0.006-percent cases per 100 000 person-years 
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Because the journal article used (Ref. 13) did not include 
the number of participants for each age group and gender, 
Equation (B1), which was used to find the 90-percent CI for 
the AF data, could not be used directly to find the 90-percent 
CI for the AFL data. However, because σ and n remain 
constant for the 90- and 95-percent CIs, they can be canceled 
out, leaving Equation (B5): 
 
( )1.6490% CI 95% CI
1.96
=
 (B5) 
The 95th and 5th percentiles and the EF for AF were found 
with following the steps. More specifically, Steps 3 and 4 for 
determining the EF from the AF section were used.  
B.4 Dental Events (Abscess, Caries, and 
Periodontal Disease) 
The following steps were used to obtain the EF for the 
dental data: 
 
(1) The 95-percent CI width was used to find σ from  
Equation (B1), where zα/2 is 1.96 for the 95-percent CI 
and width95% is 1.6 for abscess, 0.615 for caries, and 
1.93 for periodontal disease. 
(2) Next, Equation (B1) and σ were used to find the 
90-percent CI width—resulting in Equation (B2), 
where zα/2 = 1.64 for the 90-percent CI. 
The 90-percent CI width was calculated as 1.3 for  
abscess, 0.51 for caries, and 1.61 for periodontal disease. 
(3) Then, the 95th percentile was found by adding the 
90-percent CI width to the mean, and the 5th percentile 
was found by subtracting the 90-percent CI width from 
the mean. 
The 95th percentile was calculated as 4.80 for abscess, 
5.41 for caries, and 3.31 for periodontal disease. The 
5th percentile was calculated as 2.20 for abscess, 4.39 
for caries, and 0.09 for periodontal disease. 
(4) Finally, Equation (B3) was used to find EF. 
 
EF was calculated as 1.48 for abscess, 1.11 for caries, 
and 6.24 for periodontal disease. 
B.5 Gallstone Disease 
The following steps were used to obtain the EF for the 
gallstone data: 
 
(1) The 95-percent CI was used to determine the standard 
error SE from a modified form of Lapin’s equation 
(Ref. 39): 
 
 95%
2
width
SE
zα
=   (B6) 
where SE n= σ  and zα/2 =1.96 for the 95-percent 
CI. 
(2) The standard error was used to compute the 95th and 
5th percentiles according to the following definition:  
 
 95th percentile = mean + zα/2 (SE) 
 5th percentile = mean + zα/2 (SE) 
 
 
where zα/2 = 1.64 for the 90-percent CI. 
(3) Then, the EF was computed with Equation (B3). 
B.6 Herpes Zoster 
The following steps were used to obtain the EF for the 
herpes data: 
 
(1) The 95-percent CI was converted to the 90-percent CI 
using Equation (B7) from Lapin (Ref. 39, p. 311): 
 
2 widthz nα
σ
× =
 (B7) 
where zα/2 is 1.96 for the 95-percent CI and 1.64 for the 
90-percent CI. 
(2) Next, the 5th and 95th percentiles were found from the 
90-percent CI. The 95th percentile was found by adding 
the 90-percent CI width to the mean, and the 5th per-
centile was found by subtracting the 90-percent CI from 
the mean. 
(3) Finally, the EF was found from Equation (B3).  
 
Because Reference 26 did not include the number of partici-
pants or the standard deviation for each age group and gender, 
Equation (B7) could not be used directly. Entering the  
variables for the 95- and 90-percent CIs into the formula 
resulted in Equation (B8): 
 
95% 90%CI95% : width 1.96 90% : width
1.64
CI CI
n
n
σ =  
 
σ
=
 (B8) 
Because σ and n were constant for both CIs, they could be 
canceled out and substitution could be performed to yield 
Equation (B9): 
 
( )1.6490% 95%
1.96
CI CI=
 (B9) 
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B.7 Seizure 
The following steps were used with the data from Hauser, 
Annegers, and Kurland (Ref. 33 and Table 55) to obtain the 
EF for the seizure data. 
 
TABLE 55.—SEIZURE INCIDENCE OVER 10-YEAR PERIODS 
PER 100 000 PERSON-YEARS IN THE GENERAL POPULATION 
OF ROCHESTER, MINNESOTA, AGED 40 TO 54 YEARS  
Age Years that data were collected 
1935 to 
1944 
1945 to 
1954 
1955 to 
1964 
1965 to 
1974 
1975 to  
1984 
40 to 44 12 32 42 19 26 
45 to 49 7 35 29 20 23 
50 to 54 26 31 49 18 32 
 
 
The mean seizure incidence (total) per 100 000 people was 
26.73, and the standard deviation was 10.95. 
A 90-percent CI was constructed as follows:  
 0.90 = P (–z ≤ Z ≤ z) (B10) 
 
xz
n
− µ
=
 σ
 
   (B11) 
 
( )1 11 0.95 1.645
2
z − −α = Φ − = Φ = 
   (B12) 
where P is probability, z is the normal deviate of the stated 
percentile, µ is the true mean, and Φ is the cumulative density 
function. For significance level α = 0.10, sample mean x = 
26.73, standard deviation σ = 10.95, and number of samples n 
= 15, 
 0.90 = P (22.08 ≤ µ ≤ 31.38) (B13) 
Thus, the EF was found by  
 
95% 31.38 1.19
5% 22.08
EF = = =
 (B14) 
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Appendix C.—Bayesian Inference Using Gibbs  
Sampling (WinBUGS) Procedure and Code 
 
C.1 WinBUGS Procedure 
To estimate of the probability of a certain medical event, 
open WinBUGS and create a new document. Type the 
WinBUGS script for the medical event of interest (see 
Section C.2). Next, open the Specification Tool under the 
Model tab. Highlight “model” in the code and click “check 
model” in the Specification Tool. WinBUGS will respond 
with “model is syntactically correct” in the status bar. If the 
model is not syntactically correct, follow the prompts given 
by WinBUGS in the status bar to modify the code. After the 
model is checked, load the data by highlighting “list” in the 
code and click “load data.” WinBUGS will respond “data 
loaded.” Click “compile,” and WinBUGS will respond 
“model compiled.” Click “gen inits,” and WinBUGS will 
respond “initial values generated, model initialized.” Now 
open the Sample Monitor Tool under the Inference tab. Type 
“lambda” into the drop-down box labeled “node,” click 
“set,” and then select. Type “1001” into the box labeled 
“beg” and highlight “5,” “median,” and “95” under “percen-
tiles.” Now open the Update Tool under the Model tab. In 
the “updates” box, type “75000” and click “update.” When 
the model has completed its iterations, the results of the 
update may be viewed by returning to the Sample Monitor 
Tool, selecting “lambda” under node, and clicking the “stats” 
button. The lognormal Poisson distribution that was con-
structed may be viewed by clicking the “density" button on 
the Sample Monitor Tool.  
C.2 WinBUGS Code 
C.2.1 Angina 
Males 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.00063, EF= 1.77, events= 6, time= 22137.0) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000415, EF=1.48, events= 0, time= 1970.4) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000396, EF=1.46, events= 0, time= 32.0) 
 
Females 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.00047, EF= 2.08, events= 0, time= 2808.6) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000372, EF=1.94, events= 0, time= 264.8) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000365, EF=1.94, events= 0, time= 6.5) 
C.2.2 Appendicitis 
Total 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000930, EF= 1.2, events= 2, time= 1644) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.000935, EF=1.198, events= 0, time= 38.3) 
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C.2.3 Atrial Fibrillation 
Males 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=4, time=6502.7, mean=0.000640, EF=1.56) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=31.8, mean=0.000629, super=0.000902, 
sub=0.000412) 
 
Females 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=336.8, mean=0.000210, EF=2.97) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=6.5, mean=0.000202, super=0.000476, 
sub=0.000560) 
 
Total 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=4, time=6839.4, mean=0.000425, EF=1.45) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=38.3, mean=0.000443, super=0.000611, 
sub=0.000306) 
C.2.4 Atrial Flutter 
Males 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=6502.7, mean=0.0000707, EF=1.17) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=31.8, mean=0.0000705, super=0.0000821, 
sub=0.0000600) 
 
Females 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=336.8, mean=0.0000243, EF=1.18) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=6.5, mean=0.0000243, super=0.0000285, 
sub=0.0000205) 
 
  
NASA/TP—2012-217120 31 
Total 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=6839.4, mean=0.0000479, EF=1.11) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=38.3, mean=0.0000477, super=0.0000529, 
sub=0.0000429) 
C.2.5 Dental Abscess 
model { events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=19, time=475.2, mean=0.00353, EF=1.48) 
 
model { events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=31.9, mean=0.00826, EF=1.43) 
C.2.6 Dental Caries 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=168, time=475.2, mean=0.00488, EF=1.11) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=31.9, mean=0.00942, EF=1.11) 
C.2.7 Dental Periodontal Disease 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=56, time=475.2, mean=0.00168, EF=6.24) 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=31.9, mean=0.110, EF=1.26) 
C.2.8 Gallstone Disease 
Males 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=3, time=1970.4, mean=0.000769, EF=1.01) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=32.0, mean=0.0007691, EF=1.01) 
 
Females 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=264.8, mean=0.001266, EF=1.01) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=6.5, mean=0.001266, EF=1.01) 
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Total 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
time <- menpreflight + womenpreflight} 
list(events=3, menpreflight=1970.4, womenpreflight = 264.8, 
mean=0.001017, EF=1.01) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
time <- meninflight + womeninflight} 
list(events=0, meninflight=32.0, womeninflight = 6.5, 
mean=0.001017, EF=1.01) 
C.2.9 Herpes Zoster 
Males 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=8, time=1985.9, mean=0.0025, EF=1.09) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=1, time=32.5, mean=0.00250, super=0.00272, 
sub=0.00229) 
 
Females 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=273.1, mean=0.0032, EF=1.07) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=0, time=6.5, mean=0.00323, super=0.00345, 
sub=0.00302) 
 
Total 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=8, time=2259.0, mean=0.0029, EF=1.04) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2) 
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2 
EF <- pow(div, 1/2) 
div <- super/sub} 
list(events=1, time=39.0, mean=0.00290, super=0.00301, 
sub=0.00278) 
C.2.10 Renal Stones 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=74, time=17740.8, mean=0.0018, EF=2.236) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
EF <- pow(x,1/2) 
x <- p95/p5 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.00397, p95= 0.00474, p5= 0.00324, events= 0, 
time= 25.1) 
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C.2.11 Seizure 
Total 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.00027, EF= 1.19, events= 0, time= 2235.2) 
 
model {events ~ dpois(mean.poisson) 
mean.poisson <- lambda*time 
lambda ~ dlnorm(mu, tau) 
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(mean= 0.00027, EF=1.19, events= 0, time= 38.6) 
C.2.12 Stroke 
Males 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=2, time=3478.6, mean=0.00110, EF=1.567) 
 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=31.8, mean=0.000981, EF=1.482) 
 
Females 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=336.8, mean=0.000700, EF=1.773) 
 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=6.5, mean=0.000680, EF=1.739) 
 
Total 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=2, time=3815.3, mean=0.000900, EF=1.254) 
 
model {events ~ dpois(mean.poisson)  
mean.poisson <- lambda*time  
lambda ~ dlnorm(mu, tau)  
tau <- 1/pow(sigma, 2)  
sigma <- log(EF)/1.645 
mu <- log(mean) - pow(sigma, 2)/2} 
list(events=0, time=38.3, mean=0.000878, EF=1.254) 
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Appendix D.—Statistical Combination of Independent Distributions 
 
Although the objective of the current study is to obtain 
estimates of incidence rate for various medical events in 
astronauts, these rates are not always available for the events 
under investigation. Instead, rates may be available for more 
specific complications or diseases, which must then be 
combined in a statistically correct fashion to provide an 
estimate of the total incidence of the disease category under 
study. In the current study, the analysis of gallstone disease 
serves as a primary example. Urbach et al. (Ref. 25) provided 
incidence data stratified by age and gender for three different 
gallstone-related conditions: namely, acute cholecystitis, acute 
biliary pancreatitis, and acute cholangitis. For an estimate of 
total gallstone disease incidence in the general population to 
be obtained, these incidence rates—and their associated 
uncertainties—needed to be combined in a statistically 
accurate fashion. The method in which this was accomplished 
is presented in this appendix.  
Combination of individual disease incidence rates depends 
on an assumption of independence. This assumption allows 
the uncertainties of the incidences to be combined in a fashion 
dictated by the rules of probability. As noted in the following 
discussion, the variance of the scaled sum of two independent 
distributions is simply the sum of their variances, multiplied 
by the square of the scaling factor:  
Let X and Y be two independent random variables, and let 
Z = a(X + Y): 
 ( )2 2 2 2z x yaσ = σ + σ  (D1) 
Accordingly, the following relationship holds for the  
standard deviation of the combined distribution: 
 
2 2
z x yaσ = σ + σ  (D2) 
This relation was applied to the data available for the vari-
ous gallstone conditions in order to determine the combined 
incidence of general gallstone disease. The raw data presented 
in Reference 25 provided separate incidence rates for three 
different gallstone conditions and for three discrete age 
groups: 18 to 44, 45 to 64, and ≥65. Because the present study 
required an estimate of total gallstone disease incidence in the 
astronaut-like age range, 18 to 64, six separate distributions 
had to be combined in this manner for males and females in 
the three ranges. 
Assumptions were made in the interpretation of the inci-
dence rates presented in Reference 25 to leverage Equation 
(D2) in combining the uncertainties of independent distribu-
tions. (1) The incidence of a given condition in a particular 
age group was assumed to be independent of the incidence of 
the same condition in other age groups. (2) The incidence of a 
particular condition was assumed to be independent of the 
incidence of the other two conditions. (3) The incidence in 
males was assumed to be independent of the incidence in 
females. 
Reference 25 provided the annual incidence per 100 000 
persons for each category, as well as a 95-percent CI for this 
value. The standard error of each incidence rate was deter-
mined as follows:  
95% CI – (mean – 1.96 • SE, mean + 1.96 • SE) 
 
95%  upper limit 95%  lower limit
3.92
CI CISE −∴ =    (D3) 
The standard error of the mean SE is the standard deviation 
of the sample mean of a population distribution. Therefore, the 
standard error can be used in the same fashion as the standard 
deviation σ is used in Equation (D2) to properly account for 
uncertainty when independent incidence rates are combined. 
It was assumed that age groups were independent from each 
other, so an incidence rate λ for ages 18 to 64 was found for 
each specific condition by averaging the λ provided for ages 
18 to 44 and 45 to 64. The standard error for the new com-
bined distribution was determined from Equations (D2) and 
(D3): 
 
( )18 to 64 18 to 44 45 to 6412λ = λ + λ  (D4) 
 
2 2
18 to 64 18 to 44 45 to 64
1
2SE SE SE∴ = +  
This process was used for all three gallbladder conditions 
for data for both males and females to determine an incidence 
rate for each condition. These three conditions were then 
combined in a simple additive fashion, again with the assump-
tion of the independence of incidence and applying the 
formula for determining combined standard error: 
 ( )total 1 2 3λ = λ + λ + λ   
  (D5) 
 
2 2 2
total 1 2 3SE SE SE SE∴ = + +
 
This process was applied to incidence data for both males 
and females, yielding values of the total gallstone disease 
incidence. The total incidence rate was determined by averag-
ing the incidence rates for males and females, again combin-
ing the standard errors with the same procedure used to 
average the age-specific incidence rates.  
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